uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q17.110 | Q17 | What gene does the drug Loteprednol Etabonate target? | The drug Loteprednol Etabonate targets the gene NR3C1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%loteprednol etabonate%" OR LOWER(tradeNames_string) LIKE "%loteprednol etabonate%" OR LOWER(drugSynonyms_string) LIKE "%loteprednol etabonate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5556', 'drugName': 'Loteprednol Etabonate', 'tradeNames_string': 'Airex, Alrex, Eysuvis, Inveltys, Lotemax, Lotemax sm', 'drugSynonyms_string': 'CDDD 5604, CDDD-5604, HGP-1, KPI-121, Loteprednol, Loteprednol etabonate, P-5604', 'linkedDiseasesDrug_string': 'Allergic Conjunctivitis (EFO_0007141), Anterior Uveitis (EFO_1000811), Blepharitis (EFO_0009536), Cataract (MONDO_0005129), Ocular Pain (HP_0200026), Eye Inflammation (EFO_0005752), Inflammation (MP_0001845), Dry Eye Syndrome (EFO_1000906)', 'yearOfFirstApproval': 1998, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1296 | Q17 | What gene does the drug Timolol target? | The drug Timolol targets 2 genes: ADRB2 and ADRB1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%timolol%" OR LOWER(tradeNames_string) LIKE "%timolol%" OR LOWER(drugSynonyms_string) LIKE "%timolol%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_761', 'drugName': 'Timolol Maleate', 'tradeNames_string': 'Blocadren, Istalol, Timolol maleate, Timoptic, Timoptic Xe, Timoptic in ocudose, Timoptic-xe', 'drugSynonyms_string': 'Aquanil, NSC-757351, Ophtamolol, Timolol (as maleate), Timolol hydrogen maleate salt, Timolol maleate, Timolol maleate, s-enantiomer, Timololi maleas, WP-934', 'linkedDiseasesDrug_string': 'Open-Angle Glaucoma (EFO_0004190), Hemangioma (EFO_1000635), Portal Hypertension (EFO_0000666), Ocular Hypertension (EFO_1001069), Glaucoma (MONDO_0005041), Corneal Edema (EFO_1000879), Anterior Ischemic Optic Neuropathy (EFO_1000809)', 'yearOfFirstApproval': 1978, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252), ADRB1 (ENSG00000043591)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_760', 'drugName': 'Timolol Maleate', 'tradeNames_string': 'Blocadren, Istalol, Timolol maleate, Timoptic, Timoptic Xe, Timoptic in ocudose, Timoptic-xe', 'drugSynonyms_string': 'Aquanil, NSC-757351, Ophtamolol, Timolol (as maleate), Timolol hydrogen maleate salt, Timolol maleate, Timolol maleate, s-enantiomer, Timololi maleas, WP-934', 'linkedDiseasesDrug_string': 'Open-Angle Glaucoma (EFO_0004190), Hemangioma (EFO_1000635), Portal Hypertension (EFO_0000666), Ocular Hypertension (EFO_1001069), Glaucoma (MONDO_0005041), Corneal Edema (EFO_1000879), Anterior Ischemic Optic Neuropathy (EFO_1000809)', 'yearOfFirstApproval': 1978, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252), ADRB1 (ENSG00000043591)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4699', 'drugName': 'Timolol', 'tradeNames_string': 'Betim, Betimol, Blocadren, Glau-opt, Glaucol, Nyogel, Timolol, Timoptic, Tiopex', 'drugSynonyms_string': 'Blocadren, Istalol, Timolol, Timolol anhydrous, Timolol hemihydrate, Timoptic, Timoptic-XE', 'linkedDiseasesDrug_string': 'Exfoliation Syndrome (EFO_0004235), Migraine Disorder (MONDO_0005277), Open-Angle Glaucoma (EFO_0004190), Hemangioma (EFO_1000635), Cardiovascular Disease (EFO_0000319), Wet Macular Degeneration (EFO_0004683), Melanoma (EFO_0000756), Portal Hypertension (EFO_0000666), Ocular Hypertension (EFO_1001069), Injury (EFO_0000546), Glaucoma (MONDO_0005041), Hereditary Hemorrhagic Telangiectasia (MONDO_0019180), Corneal Edema (EFO_1000879), Varicose Ulcer (EFO_1001923), Anterior Ischemic Optic Neuropathy (EFO_1000809)', 'yearOfFirstApproval': 1978, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4698', 'drugName': 'Timolol', 'tradeNames_string': 'Betim, Betimol, Blocadren, Glau-opt, Glaucol, Nyogel, Timolol, Timoptic, Tiopex', 'drugSynonyms_string': 'Blocadren, Istalol, Timolol, Timolol anhydrous, Timolol hemihydrate, Timoptic, Timoptic-XE', 'linkedDiseasesDrug_string': 'Exfoliation Syndrome (EFO_0004235), Migraine Disorder (MONDO_0005277), Open-Angle Glaucoma (EFO_0004190), Hemangioma (EFO_1000635), Cardiovascular Disease (EFO_0000319), Wet Macular Degeneration (EFO_0004683), Melanoma (EFO_0000756), Portal Hypertension (EFO_0000666), Ocular Hypertension (EFO_1001069), Injury (EFO_0000546), Glaucoma (MONDO_0005041), Hereditary Hemorrhagic Telangiectasia (MONDO_0019180), Corneal Edema (EFO_1000879), Varicose Ulcer (EFO_1001923), Anterior Ischemic Optic Neuropathy (EFO_1000809)', 'yearOfFirstApproval': 1978, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.503 | Q17 | What gene does the drug Loxapine Succinate target? | The drug Loxapine Succinate targets 5 genes: DRD4, HTR2A, DRD2, HTR2C and DRD3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%loxapine succinate%" OR LOWER(tradeNames_string) LIKE "%loxapine succinate%" OR LOWER(drugSynonyms_string) LIKE "%loxapine succinate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_488', 'drugName': 'Loxapine Succinate', 'tradeNames_string': 'Loxapac, Loxapine, Loxapine succinate, Loxitane', 'drugSynonyms_string': 'CL 71563, CL-71563, Loxapine succinate, NSC-759578', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1975, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2C (ENSG00000147246), HTR2A (ENSG00000102468), DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_489', 'drugName': 'Loxapine Succinate', 'tradeNames_string': 'Loxapac, Loxapine, Loxapine succinate, Loxitane', 'drugSynonyms_string': 'CL 71563, CL-71563, Loxapine succinate, NSC-759578', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1975, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2C (ENSG00000147246), HTR2A (ENSG00000102468), DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_490', 'drugName': 'Loxapine Succinate', 'tradeNames_string': 'Loxapac, Loxapine, Loxapine succinate, Loxitane', 'drugSynonyms_string': 'CL 71563, CL-71563, Loxapine succinate, NSC-759578', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1975, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2C (ENSG00000147246), HTR2A (ENSG00000102468), DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696)', 'numberLinkedTargets': 5}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1981 | Q17 | What gene does the drug Colchicine target? | The drug Colchicine targets 15 genes: TUBB, TUBA4A, TUBA3E, TUBB3, TUBB4B, TUBB2A, TUBA1A, TUBA1C, TUBB1, TUBB2B, TUBB8, TUBB6, TUBB4A, TUBA3C and TUBA1B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%colchicine%" OR LOWER(tradeNames_string) LIKE "%colchicine%" OR LOWER(drugSynonyms_string) LIKE "%colchicine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4743', 'drugName': 'Colchicine', 'tradeNames_string': 'Colchicine, Colcrys, Gloperba, Mitigare', 'drugSynonyms_string': '(-)-colchicine, Colchcine, Colchicine, Colchicinum, Colchineos, Colchisol, NSC-757', 'linkedDiseasesDrug_string': "Coronary Artery Disease (EFO_0001645), Non-St Elevation Myocardial Infarction (EFO_0008586), Behcet'S Syndrome (EFO_0003780), Covid-19 (MONDO_0100096), Vasculitis (EFO_0006803), St Elevation Myocardial Infarction (EFO_0008585), Lung Disease (EFO_0003818), Coronavirus Infectious Disease (EFO_0007224), Primary Biliary Cirrhosis (EFO_1001486), Atrial Fibrillation (EFO_0000275), Prostate Cancer (MONDO_0008315), Hypertension (EFO_0000537), Intracranial Hemorrhage (EFO_0000551), Aphthous Ulcer (EFO_0003938), Acute Coronary Syndrome (EFO_0005672), Cardiac Arrhythmia (EFO_0004269), Postpericardiotomy Syndrome (EFO_1001404), Cholangiocarcinoma (EFO_0005221), Familial Mediterranean Fever (MONDO_0018088), Asthma (MONDO_0004979), Viral Pneumonia (EFO_0007541), Proliferative Vitreoretinopathy (EFO_1001129), Myocardial Infarction (EFO_0000612), Chronic Hepatitis C Virus Infection (EFO_0004220), Gout (EFO_0004274), Heart Disease (EFO_0003777), Chronic Kidney Disease (EFO_0003884), Urogenital Neoplasm (EFO_0003863), Osteoarthritis (MONDO_0005178), Diabetic Nephropathy (EFO_0000401), Amyotrophic Lateral Sclerosis (MONDO_0004976), Neoplasm (EFO_0000616), Heart Failure (EFO_0003144), Pericarditis (EFO_0007427), Vascular Disease (EFO_0004264), Atherosclerosis (EFO_0003914), Severe Acute Respiratory Syndrome (EFO_0000694), Cirrhosis Of Liver (EFO_0001422)", 'yearOfFirstApproval': 1961, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'numberLinkedTargets': 15}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.869 | Q17 | What gene does the drug Quinidine Sulfate target? | The drug Quinidine Sulfate targets 10 genes: SCN1A, SCN9A, SCN7A, SCN8A, SCN11A, SCN10A, SCN2A, SCN5A, SCN4A and SCN3A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%quinidine sulfate%" OR LOWER(tradeNames_string) LIKE "%quinidine sulfate%" OR LOWER(drugSynonyms_string) LIKE "%quinidine sulfate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3310', 'drugName': 'Quinidine Sulfate', 'tradeNames_string': 'Cin-quin, Quinicardine, Quinidex, Quinidine sulfate, Quinora', 'drugSynonyms_string': 'AVP-786 COMPONENT QUINIDINE SULFATE, NSC-10004, QUINIDINE SULFATE COMPONENT OF AVP-786, Quinidex extentabs, Quinidine sulfate, Quinidine sulfate anhydrous, Quinidine sulfate dihydrate, Quinidine sulfate hydrate, Quinidine sulphate, Quinidine sulphate anhydrous, Quinidine sulphate dihydrate, Quinidine, sulfate (2:1) (salt), Quinidini sulfas', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Amyotrophic Lateral Sclerosis (MONDO_0004976)', 'yearOfFirstApproval': 1962, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.748 | Q17 | What gene does the drug Teniposide target? | The drug Teniposide targets 2 genes: TOP2A and TOP2B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%teniposide%" OR LOWER(tradeNames_string) LIKE "%teniposide%" OR LOWER(drugSynonyms_string) LIKE "%teniposide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2612', 'drugName': 'Teniposide', 'tradeNames_string': 'Vumon', 'drugSynonyms_string': 'NSC-122819, Teniposide, VM-26, VM26', 'linkedDiseasesDrug_string': 'Lymphoma (EFO_0000574), Leukemia (EFO_0000565), Acute Lymphoblastic Leukemia (EFO_0000220), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 1992, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TOP2A (ENSG00000131747), TOP2B (ENSG00000077097)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1015 | Q17 | What gene does the drug Cisatracurium target? | The drug Cisatracurium targets 5 genes: CHRNB1, CHRNA1, CHRND, CHRNE and CHRNG. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cisatracurium%" OR LOWER(tradeNames_string) LIKE "%cisatracurium%" OR LOWER(drugSynonyms_string) LIKE "%cisatracurium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3167', 'drugName': 'Cisatracurium', 'tradeNames_string': 'Nimbex', 'drugSynonyms_string': 'Cisatracurium, Cisatracurium cation, Cisatracurium ion', 'linkedDiseasesDrug_string': 'Acute Respiratory Distress Syndrome (EFO_1000637)', 'yearOfFirstApproval': 1995, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_3676', 'drugName': 'Cisatracurium Besylate', 'tradeNames_string': 'Cisatracurium besylate, Cisatracurium besylate preservative free, Nimbex, Nimbex preservative free', 'drugSynonyms_string': '51 W89, 51-W-89, 51-W89, 51W-89, 51W89, Cisatracurium (as besilate), Cisatracurium besilate, Cisatracurium besylate', 'linkedDiseasesDrug_string': 'Acute Respiratory Distress Syndrome (EFO_1000637)', 'yearOfFirstApproval': 1995, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'numberLinkedTargets': 5}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1315 | Q17 | What gene does the drug Bromocriptine target? | The drug Bromocriptine targets 3 genes: DRD3, DRD4 and DRD2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bromocriptine%" OR LOWER(tradeNames_string) LIKE "%bromocriptine%" OR LOWER(drugSynonyms_string) LIKE "%bromocriptine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_630', 'drugName': 'Bromocriptine', 'tradeNames_string': 'Parlodel', 'drugSynonyms_string': '2-bromo-.alpha.-ergocryptine, Bromergocryptine, Bromocriptine, CB-154, Ergocryptine, 2-bromo-, SANDOZ 15-754', 'linkedDiseasesDrug_string': 'Hypogonadism (MONDO_0002146), Adenomyosis (EFO_1001757), Alzheimer Disease (MONDO_0004975), Acromegaly (EFO_1001485), Intellectual Disability (HP_0001249), Infertility (EFO_0000545), Obesity (EFO_0001073), Parkinson Disease (MONDO_0005180), Adenoma (EFO_0000232), Ovarian Hyperstimulation Syndrome (MONDO_0011972), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148), Anorexia Nervosa (MONDO_0005351), Hyperprolactinemia (EFO_0007319)', 'yearOfFirstApproval': 1978, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_4746', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_string': 'Bromocriptine mesylate, Cycloset, Parlodel', 'drugSynonyms_string': '2-bromoergocryptine mesylate, Bromocriptine mesilate, Bromocriptine mesylate, Bromocriptine methanesulfonate, CB-154, CB-154 MESYLATE, Cb-154 mesilate, NSC-755915', 'linkedDiseasesDrug_string': 'Hypogonadism (MONDO_0002146), Acromegaly (EFO_1001485), Infertility (EFO_0000545), Parkinson Disease (MONDO_0005180), Adenoma (EFO_0000232), Type 2 Diabetes Mellitus (MONDO_0005148), Hyperprolactinemia (EFO_0007319)', 'yearOfFirstApproval': 1978, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1297 | Q17 | What gene does the drug Diacetylmorphine target? | The drug Diacetylmorphine targets the gene OPRM1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%diacetylmorphine%" OR LOWER(tradeNames_string) LIKE "%diacetylmorphine%" OR LOWER(drugSynonyms_string) LIKE "%diacetylmorphine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3858', 'drugName': 'Diacetylmorphine', 'tradeNames_string': '', 'drugSynonyms_string': 'Diacetylmorphine, IDS-NH-001, IDS-NH-001(SECT.3), J6.494G', 'linkedDiseasesDrug_string': 'Opioid Use Disorder (EFO_0010702), Drug Dependence (EFO_0003890), Opioid Dependence (EFO_0005611), Heroin Dependence (EFO_0004240)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.609 | Q17 | What gene does the drug Metocurine target? | The drug Metocurine targets 5 genes: CHRNB1, CHRNA1, CHRND, CHRNE and CHRNG. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%metocurine%" OR LOWER(tradeNames_string) LIKE "%metocurine%" OR LOWER(drugSynonyms_string) LIKE "%metocurine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2699', 'drugName': 'Metocurine Iodide', 'tradeNames_string': 'Metubine iodide', 'drugSynonyms_string': 'Dimethyl tubocurarine iodide, Dimethylchondrocurarine iodide, Dimethyltubocurarinium iodide, Metocurine iodide, NSC-36388', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_4392', 'drugName': 'Metocurine', 'tradeNames_string': '', 'drugSynonyms_string': 'Dimethyl tubocurarine, Dimethyltubocurarine, Dimethyltubocurarinium, Metocurine, Metocurine cation, Metocurine ion', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'numberLinkedTargets': 5}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1362 | Q17 | What gene does the drug Alirocumab target? | The drug Alirocumab targets the gene PCSK9. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%alirocumab%" OR LOWER(tradeNames_string) LIKE "%alirocumab%" OR LOWER(drugSynonyms_string) LIKE "%alirocumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1637', 'drugName': 'Alirocumab', 'tradeNames_string': 'Praluent', 'drugSynonyms_string': 'Alirocumab, REGN-727, REGN727, SAR-236553, SAR236553', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Coronary Artery Disease (EFO_0001645), Sepsis (HP_0100806), Familial Hypercholesterolemia (EFO_0004911), Cardiovascular Disease (EFO_0000319), Hypercholesterolemia (HP_0003124), Homozygous Familial Hypercholesterolemia (MONDO_0018328), Disorder Of Lipid Metabolism (Orphanet_309005), Atherosclerosis (EFO_0003914)', 'yearOfFirstApproval': 2015, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PCSK9 (ENSG00000169174)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.75 | Q17 | What gene does the drug Echothiophate Iodide target? | The drug Echothiophate Iodide targets the gene ACHE. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%echothiophate iodide%" OR LOWER(tradeNames_string) LIKE "%echothiophate iodide%" OR LOWER(drugSynonyms_string) LIKE "%echothiophate iodide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2129', 'drugName': 'Echothiophate Iodide', 'tradeNames_string': 'Phospholine iodide', 'drugSynonyms_string': '217-MI, Echodide, Echothiophate iodide, Ecostigmine iodide, Ecothiopate iodide', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1960, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ACHE (ENSG00000087085)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1082 | Q17 | What gene does the drug Frovatriptan target? | The drug Frovatriptan targets 2 genes: HTR1B and HTR1D. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%frovatriptan%" OR LOWER(tradeNames_string) LIKE "%frovatriptan%" OR LOWER(drugSynonyms_string) LIKE "%frovatriptan%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3513', 'drugName': 'Frovatriptan', 'tradeNames_string': 'Migard, Mylatrip', 'drugSynonyms_string': 'Allergo filmtabletten, Frova, Frovatriptan', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277), Pain (EFO_0003843)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1D (ENSG00000179546), HTR1B (ENSG00000135312)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3512', 'drugName': 'Frovatriptan', 'tradeNames_string': 'Migard, Mylatrip', 'drugSynonyms_string': 'Allergo filmtabletten, Frova, Frovatriptan', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277), Pain (EFO_0003843)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1D (ENSG00000179546), HTR1B (ENSG00000135312)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4362', 'drugName': 'Frovatriptan Succinate', 'tradeNames_string': 'Frova, Frovatriptan succinate', 'drugSynonyms_string': 'Frovatriptan succinate, Frovatriptan succinate hydrate, Frovelan, Miguard, NSC-760422, SB 209509 AX, SB 209509-AX, SB-209509-AX, SB-209509AX, VML 251, VML-251', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1B (ENSG00000135312), HTR1D (ENSG00000179546)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4361', 'drugName': 'Frovatriptan Succinate', 'tradeNames_string': 'Frova, Frovatriptan succinate', 'drugSynonyms_string': 'Frovatriptan succinate, Frovatriptan succinate hydrate, Frovelan, Miguard, NSC-760422, SB 209509 AX, SB 209509-AX, SB-209509-AX, SB-209509AX, VML 251, VML-251', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1B (ENSG00000135312), HTR1D (ENSG00000179546)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1214 | Q17 | What gene does the drug Bepridil Hydrochloride target? | The drug Bepridil Hydrochloride targets 26 genes: CACNA1C, CACNA1H, CACNG2, CACNG7, CACNA2D1, CACNG6, CACNA1B, CACNG5, CACNG3, CACNG1, CACNB3, CACNB4, CACNA1S, CACNA2D3, CACNA1A, CACNA2D4, CACNA1D, CACNB2, CACNA1G, CACNA1I, CACNG8, CACNB1, CACNG4, CACNA1E, CACNA2D2 and CACNA1F. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bepridil hydrochloride%" OR LOWER(tradeNames_string) LIKE "%bepridil hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%bepridil hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4565', 'drugName': 'Bepridil Hydrochloride', 'tradeNames_string': 'Bepadin, Vascor', 'drugSynonyms_string': 'Bepridil hydrochloride, Bepridil hydrochloride hydrate, CERM 1978, CERM-1978, Cordium, NSC-758390, Unicordium', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1990, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1H (ENSG00000196557), CACNA2D1 (ENSG00000153956), CACNA1C (ENSG00000151067), CACNA2D3 (ENSG00000157445), CACNA1S (ENSG00000081248), CACNA2D2 (ENSG00000007402), CACNA1D (ENSG00000157388), CACNA1A (ENSG00000141837), CACNA1B (ENSG00000148408), CACNA1G (ENSG00000006283), CACNA2D4 (ENSG00000151062), CACNA1I (ENSG00000100346), CACNA1F (ENSG00000102001), CACNA1E (ENSG00000198216), CACNB4 (ENSG00000182389), CACNB2 (ENSG00000165995), CACNB1 (ENSG00000067191), CACNB3 (ENSG00000167535), CACNG7 (ENSG00000105605), CACNG5 (ENSG00000075429), CACNG2 (ENSG00000166862), CACNG4 (ENSG00000075461), CACNG8 (ENSG00000142408), CACNG3 (ENSG00000006116), CACNG6 (ENSG00000130433), CACNG1 (ENSG00000108878)', 'numberLinkedTargets': 26}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1167 | Q17 | What gene does the drug Ibufenac target? | The drug Ibufenac targets 2 genes: PTGS2 and PTGS1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ibufenac%" OR LOWER(tradeNames_string) LIKE "%ibufenac%" OR LOWER(drugSynonyms_string) LIKE "%ibufenac%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3586', 'drugName': 'Ibufenac', 'tradeNames_string': 'Dytransin', 'drugSynonyms_string': '(p-isobutylphenyl)acetic acid, Ibufenac, NSC-99976, RD 11654, RD-11654', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.625 | Q17 | What gene does the drug Traxoprodil target? | The drug Traxoprodil is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: GRIN1 and GRIN2B | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%traxoprodil%" OR LOWER(tradeNames_string) LIKE "%traxoprodil%" OR LOWER(drugSynonyms_string) LIKE "%traxoprodil%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3399', 'drugName': 'Traxoprodil', 'tradeNames_string': '', 'drugSynonyms_string': 'CP-101,606, CP-101606, Cp-101,606, Traxoprodil', 'linkedDiseasesDrug_string': 'Stroke (EFO_0000712), Major Depressive Disorder (MONDO_0002009), Parkinson Disease (MONDO_0005180)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2B (ENSG00000273079)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.487 | Q17 | What gene does the drug Testolactone target? | The drug Testolactone targets the gene CYP19A1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%testolactone%" OR LOWER(tradeNames_string) LIKE "%testolactone%" OR LOWER(drugSynonyms_string) LIKE "%testolactone%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2073', 'drugName': 'Testolactone', 'tradeNames_string': 'Fludestrin, Teslac', 'drugSynonyms_string': 'NSC-23759, SQ 9538, SQ-9538, Teolit, Testolactone, Testolactone ciii', 'linkedDiseasesDrug_string': 'Precocious Puberty (MONDO_0000088)', 'yearOfFirstApproval': 1969, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CYP19A1 (ENSG00000137869)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1579 | Q17 | What gene does the drug Amitifadine target? | The drug Amitifadine is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 3 genes: SLC6A4, SLC6A2 and SLC6A3 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%amitifadine%" OR LOWER(tradeNames_string) LIKE "%amitifadine%" OR LOWER(drugSynonyms_string) LIKE "%amitifadine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1040', 'drugName': 'Amitifadine', 'tradeNames_string': '', 'drugSynonyms_string': 'Amitifadine, DOV 21947, DOV-21,947, DOV-21947, EB1010', 'linkedDiseasesDrug_string': 'Major Depressive Disorder (MONDO_0002009)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576), SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.512 | Q17 | What gene does the drug Vorapaxar target? | The drug Vorapaxar targets the gene F2R. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%vorapaxar%" OR LOWER(tradeNames_string) LIKE "%vorapaxar%" OR LOWER(drugSynonyms_string) LIKE "%vorapaxar%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_713', 'drugName': 'Vorapaxar Sulfate', 'tradeNames_string': 'Zontivity', 'drugSynonyms_string': 'SCH 530348, SCH-530348, Vorapaxar sulfate', 'linkedDiseasesDrug_string': 'Stroke (EFO_0000712), Peripheral Arterial Disease (EFO_0004265), Acute Coronary Syndrome (EFO_0005672), Myocardial Infarction (EFO_0000612)', 'yearOfFirstApproval': 2014, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'F2R (ENSG00000181104)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1286', 'drugName': 'Vorapaxar', 'tradeNames_string': '', 'drugSynonyms_string': 'SCH-530348, Vorapaxar', 'linkedDiseasesDrug_string': 'Recurrent Thrombophlebitis (HP_0004419), Hiv Infection (EFO_0000764), Cerebral Infarction (MONDO_0002679), Stroke (EFO_0000712), Peripheral Arterial Disease (EFO_0004265), Myocardial Infarction (EFO_0000612), Acute Coronary Syndrome (EFO_0005672)', 'yearOfFirstApproval': 2014, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'F2R (ENSG00000181104)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.740 | Q17 | What gene does the drug Lasmiditan target? | The drug Lasmiditan targets the gene HTR1F. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lasmiditan%" OR LOWER(tradeNames_string) LIKE "%lasmiditan%" OR LOWER(drugSynonyms_string) LIKE "%lasmiditan%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4144', 'drugName': 'Lasmiditan', 'tradeNames_string': '', 'drugSynonyms_string': 'COL-144, LY573144, Lasmiditan', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277), Drug Dependence (EFO_0003890)', 'yearOfFirstApproval': 2020, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1F (ENSG00000179097)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1894', 'drugName': 'Lasmiditan Succinate', 'tradeNames_string': 'Reyvow', 'drugSynonyms_string': 'LY-573144, LY-683974, LY683974, Lasmiditan hemisuccinate, Lasmiditan succinate', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277)', 'yearOfFirstApproval': 2020, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1F (ENSG00000179097)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.762 | Q17 | What gene does the drug Pegfilgrastim target? | The drug Pegfilgrastim targets the gene CSF3R. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pegfilgrastim%" OR LOWER(tradeNames_string) LIKE "%pegfilgrastim%" OR LOWER(drugSynonyms_string) LIKE "%pegfilgrastim%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4822', 'drugName': 'Lipegfilgrastim', 'tradeNames_string': 'Lonquex', 'drugSynonyms_string': 'Lipegfilgrastim, XM-22, XM22', 'linkedDiseasesDrug_string': 'Ewing Sarcoma (EFO_0000174), Lymphoma (EFO_0000574), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CSF3R (ENSG00000119535)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4194', 'drugName': 'Pegfilgrastim', 'tradeNames_string': 'Neulasta, Neulasta sureclick', 'drugSynonyms_string': 'Chs-1701, Fulphila, Fylnetra, Granulocyte colony-stimulating factor pegfilgrastim, Lupifil-p, MYL-1401H, Neupopeg, Nyvepria, Peg-filgrastim, Pegfilgrastim, Pegfilgrastim (neulasta), Pegfilgrastim apgf, Pegfilgrastim biosimilar - lupin, Pegfilgrastim bmez, Pegfilgrastim cbqv, Pegfilgrastim for bioassay, Pegfilgrastim jmdb, Pegfilgrastim pbbk, Pegfilgrastim-apgf, Pegfilgrastim-bmez, Pegfilgrastim-cbqv, Pegfilgrastim-jmdb, Pegfilgrastim-ljfd, Pegfilgrastim-pbbk, Ql-0605, Ql0605, TPI-120, Udenyca, Ziextenzo', 'linkedDiseasesDrug_string': 'Neuroblastoma (EFO_0000621), Multiple Myeloma (EFO_0001378), Cancer (MONDO_0004992), Medulloblastoma (EFO_0002939), Infection (EFO_0000544), Non-Hodgkins Lymphoma (EFO_0005952), Myeloid Leukemia (MONDO_0004643), Urothelial Carcinoma (EFO_0008528), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Lymphoid Neoplasm (EFO_0001642), Breast Carcinoma (EFO_0000305), Breast Neoplasm (EFO_0003869), Malignant Colon Neoplasm (MONDO_0021063), Prostate Cancer (MONDO_0008315), Uterine Neoplasm (EFO_0003859), Mantle Cell Lymphoma (EFO_1001469), Breast Cancer (MONDO_0007254), Neutropenia (MONDO_0001475), Acute Lymphoblastic Leukemia (EFO_0000220), Male Breast Carcinoma (EFO_0006861), Lymphoma (EFO_0000574), Acute Myeloid Leukemia (EFO_0000222), Wilms Tumor (MONDO_0006058), Aplastic Anemia (HP_0001915), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Diffuse Large B-Cell Lymphoma (EFO_0000403), Urethra Cancer (MONDO_0004192), Retinoblastoma (MONDO_0008380), Lung Adenocarcinoma (EFO_0000571), Urinary Bladder Carcinoma (MONDO_0004986), Small Cell Lung Carcinoma (EFO_0000702), Neoplasm Of Mature B-Cells (EFO_0000096), Triple-Negative Breast Cancer (EFO_0005537), Renal Cell Carcinoma (EFO_0000681), Peritoneum Cancer (MONDO_0002087), Cutaneous T-Cell Lymphoma (EFO_0002913), Hodgkins Lymphoma (EFO_0000183), Cervical Cancer (MONDO_0002974), Brain Cancer (MONDO_0001657), Rectum Cancer (EFO_1000657), Head And Neck Malignant Neoplasia (EFO_0006859), Follicular Lymphoma (MONDO_0018906), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Nasopharyngeal Neoplasm (EFO_0004252), Non-Small Cell Lung Carcinoma (EFO_0003060), Classic Hodgkin Lymphoma (MONDO_0009348), Osteosarcoma (EFO_0000637), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Type 1 Diabetes Mellitus (MONDO_0005147), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211), Esophageal Cancer (MONDO_0007576), Germ Cell Tumor (EFO_0000514)', 'yearOfFirstApproval': 2002, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CSF3R (ENSG00000119535)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1990 | Q17 | What gene does the drug Clotiazepam target? | The drug Clotiazepam targets 16 genes: GABRG2, GABRE, GABRA4, GABRQ, GABRD, GABRA3, GABRP, GABRA5, GABRG3, GABRB2, GABRB3, GABRG1, GABRA2, GABRB1, GABRA6 and GABRA1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%clotiazepam%" OR LOWER(tradeNames_string) LIKE "%clotiazepam%" OR LOWER(drugSynonyms_string) LIKE "%clotiazepam%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6147', 'drugName': 'Clotiazepam', 'tradeNames_string': 'Clozan', 'drugSynonyms_string': 'Clotiazepam', 'linkedDiseasesDrug_string': 'Anxiety (EFO_0005230)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 16}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.784 | Q17 | What gene does the drug Amsacrine target? | The drug Amsacrine targets 2 genes: TOP2A and TOP2B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%amsacrine%" OR LOWER(tradeNames_string) LIKE "%amsacrine%" OR LOWER(drugSynonyms_string) LIKE "%amsacrine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3938', 'drugName': 'Amsacrine', 'tradeNames_string': 'Amsidyl', 'drugSynonyms_string': 'Acridinylanisidide, Amekrin, Amsacrine, Amsidil, Amsidine, CI-880, Lamasine, M-AMSA, NCI-249992, NSC-156303, NSC-249992, SN-11841, SN-21429', 'linkedDiseasesDrug_string': 'Myelodysplastic Syndrome (EFO_0000198), Acute Myeloid Leukemia (EFO_0000222), Leukemia (EFO_0000565), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TOP2A (ENSG00000131747), TOP2B (ENSG00000077097)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1763 | Q17 | What gene does the drug Dupilumab target? | The drug Dupilumab targets the gene IL4R. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dupilumab%" OR LOWER(tradeNames_string) LIKE "%dupilumab%" OR LOWER(drugSynonyms_string) LIKE "%dupilumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2283', 'drugName': 'Dupilumab', 'tradeNames_string': 'Dupixent, Regn668, sar231893', 'drugSynonyms_string': 'Dupilumab, REGN-668, REGN668, SAR-231893, SAR231893', 'linkedDiseasesDrug_string': 'Allergic Bronchopulmonary Aspergillosis (EFO_0007140), Covid-19 (MONDO_0100096), Allergic Rhinitis (EFO_0005854), Urticaria (EFO_0005531), Neurodermatitis (EFO_1000740), Nasal Polyposis (HP_0100582), Prostate Cancer (MONDO_0008315), Atopic Eczema (EFO_0000274), Netherton Syndrome (MONDO_0009735), Bullous Pemphigoid (EFO_0007187), Angioedema (EFO_0005532), Pruritus (HP_0000989), Peanut Allergic Reaction (EFO_0007425), Keloid (EFO_0004212), Nasal Cavity Polyp (EFO_1000391), Allergic Conjunctivitis (EFO_0007141), Sinusitis (EFO_0007486), Asthma (MONDO_0004979), Respiratory System Disease (EFO_0000684), Alopecia Areata (EFO_0004192), Chronic Obstructive Pulmonary Disease (EFO_0000341), Eczema (HP_0000964), Localised Scleroderma (EFO_1001361), Non-Small Cell Lung Carcinoma (EFO_0003060), Eosinophilic Esophagitis (EFO_0004232), Dermatitis (MONDO_0002406)', 'yearOfFirstApproval': 2017, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'IL4R (ENSG00000077238)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.848 | Q17 | What gene does the drug Sofpironium Bromide target? | The drug Sofpironium Bromide is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 5 genes: CHRM2, CHRM4, CHRM1, CHRM5 and CHRM3 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%sofpironium bromide%" OR LOWER(tradeNames_string) LIKE "%sofpironium bromide%" OR LOWER(drugSynonyms_string) LIKE "%sofpironium bromide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5796', 'drugName': 'Sofpironium Bromide', 'tradeNames_string': '', 'drugSynonyms_string': 'BBI-4000, Sofpironium bromide', 'linkedDiseasesDrug_string': 'Hyperhidrosis (HP_0000975)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM4 (ENSG00000180720), CHRM1 (ENSG00000168539), CHRM2 (ENSG00000181072), CHRM5 (ENSG00000184984)', 'numberLinkedTargets': 5}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.315 | Q17 | What gene does the drug Haloperidol target? | The drug Haloperidol targets 4 genes: DRD3, HTR2A, DRD4 and DRD2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%haloperidol%" OR LOWER(tradeNames_string) LIKE "%haloperidol%" OR LOWER(drugSynonyms_string) LIKE "%haloperidol%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_461', 'drugName': 'Haloperidol Decanoate', 'tradeNames_string': 'Haldol, Haldol Dec, Haloperidol decanoate', 'drugSynonyms_string': 'Halomonth, Haloperidol decanoate, R-13,672, R-13672', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Conduct Disorder (EFO_0004216), Mental Or Behavioural Disorder (EFO_0000677), Delirium (EFO_0009267), Tourette Syndrome (EFO_0004895), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 1986, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696), HTR2A (ENSG00000102468)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_5257', 'drugName': 'Haloperidol', 'tradeNames_string': 'Dolpin, Dozic, Fortunan, Haldol, Haldol solutab, Haloperidol, Kentace, Keselen, Serenace', 'drugSynonyms_string': 'Haloperidol, Haloperidol decanoate impurity, haloperidol-, MCN-JR-1625, NSC-170973, NSC-615296, R-1625', 'linkedDiseasesDrug_string': 'Alzheimer Disease (MONDO_0004975), Nausea (HP_0002018), Agitation (HP_0000713), Tourette Syndrome (EFO_0004895), Conduct Disorder (EFO_0004216), Mood Disorder (EFO_0004247), Nicotine Dependence (EFO_0003768), Huntington Disease (MONDO_0007739), Schizoaffective Disorder (EFO_0005411), Dementia (HP_0000726), Anxiety (EFO_0005230), Aggressive Behavior (EFO_0003015), Methamphetamine Dependence (EFO_0004701), Delirium (EFO_0009267), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Psychosis (EFO_0005407), Post-Operative Sign Or Symptom (EFO_0005323), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 1967, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696), HTR2A (ENSG00000102468)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_5256', 'drugName': 'Haloperidol', 'tradeNames_string': 'Dolpin, Dozic, Fortunan, Haldol, Haldol solutab, Haloperidol, Kentace, Keselen, Serenace', 'drugSynonyms_string': 'Haloperidol, Haloperidol decanoate impurity, haloperidol-, MCN-JR-1625, NSC-170973, NSC-615296, R-1625', 'linkedDiseasesDrug_string': 'Alzheimer Disease (MONDO_0004975), Nausea (HP_0002018), Agitation (HP_0000713), Tourette Syndrome (EFO_0004895), Conduct Disorder (EFO_0004216), Mood Disorder (EFO_0004247), Nicotine Dependence (EFO_0003768), Huntington Disease (MONDO_0007739), Schizoaffective Disorder (EFO_0005411), Dementia (HP_0000726), Anxiety (EFO_0005230), Aggressive Behavior (EFO_0003015), Methamphetamine Dependence (EFO_0004701), Delirium (EFO_0009267), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Psychosis (EFO_0005407), Post-Operative Sign Or Symptom (EFO_0005323), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 1967, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696), HTR2A (ENSG00000102468)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_5162', 'drugName': 'Haloperidol Lactate', 'tradeNames_string': 'Haldol, Haloperidol intensol, Haloperidol lactate', 'drugSynonyms_string': 'Haloperidol lactate', 'linkedDiseasesDrug_string': 'Schizophrenia (MONDO_0005090), Agitation (HP_0000713), Schizoaffective Disorder (EFO_0005411)', 'yearOfFirstApproval': 1967, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_460', 'drugName': 'Haloperidol Decanoate', 'tradeNames_string': 'Haldol, Haldol Dec, Haloperidol decanoate', 'drugSynonyms_string': 'Halomonth, Haloperidol decanoate, R-13,672, R-13672', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Conduct Disorder (EFO_0004216), Mental Or Behavioural Disorder (EFO_0000677), Delirium (EFO_0009267), Tourette Syndrome (EFO_0004895), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 1986, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696), HTR2A (ENSG00000102468)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_5161', 'drugName': 'Haloperidol Lactate', 'tradeNames_string': 'Haldol, Haloperidol intensol, Haloperidol lactate', 'drugSynonyms_string': 'Haloperidol lactate', 'linkedDiseasesDrug_string': 'Schizophrenia (MONDO_0005090), Agitation (HP_0000713), Schizoaffective Disorder (EFO_0005411)', 'yearOfFirstApproval': 1967, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.816 | Q17 | What gene does the drug Zileuton target? | The drug Zileuton targets the gene ALOX5. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%zileuton%" OR LOWER(tradeNames_string) LIKE "%zileuton%" OR LOWER(drugSynonyms_string) LIKE "%zileuton%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_953', 'drugName': 'Zileuton', 'tradeNames_string': 'Zyflo, Zyflo cr', 'drugSynonyms_string': 'A-64077, ABBOTT-64077, NSC-730712, NSC-759277, Zileuton', 'linkedDiseasesDrug_string': 'Asthma (MONDO_0004979), Lung Cancer (MONDO_0008903), Nicotine Dependence (EFO_0003768), Sickle Cell Anemia (MONDO_0011382), Chronic Obstructive Pulmonary Disease (EFO_0000341), Inflammation (MP_0001845), Acne (EFO_0003894), Idiopathic Pulmonary Fibrosis (EFO_0000768), Chronic Myelogenous Leukemia (EFO_0000339)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ALOX5 (ENSG00000012779)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.411 | Q17 | What gene does the drug Esketamine target? | The drug Esketamine targets 7 genes: GRIN2B, GRIN2A, GRIN3A, GRIN2D, GRIN3B, GRIN1 and GRIN2C. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%esketamine%" OR LOWER(tradeNames_string) LIKE "%esketamine%" OR LOWER(drugSynonyms_string) LIKE "%esketamine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4482', 'drugName': 'Esketamine', 'tradeNames_string': '', 'drugSynonyms_string': '(-)-ketamine, Esketamine, Jnj-54135419, Keta-s, Ketamine, (s)-, Ketamine, s-, Ketaved, L-ketamine, S-(-)-ketamine, S-ketamine', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Unipolar Depression (EFO_0003761), Drug Dependence (EFO_0003890), Liver Disease (EFO_0001421), Pain (EFO_0003843), Kidney Disease (EFO_0003086), Tinnitus (HP_0000360), Major Depressive Disorder (MONDO_0002009), Allergic Rhinitis (EFO_0005854), Depressive Disorder (MONDO_0002050)', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785)', 'numberLinkedTargets': 7}, {'UUID': 'DrugGeneTargets_v2_817', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_string': 'Spravato', 'drugSynonyms_string': 'AM-101, Esketamine hydrochloride, Ketamine hydrochloride, (s)-, Ketamine hydrochloride, s-, Ketanest s', 'linkedDiseasesDrug_string': 'Tinnitus (HP_0000360), Unipolar Depression (EFO_0003761), Major Depressive Disorder (MONDO_0002009), Pain (EFO_0003843)', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785)', 'numberLinkedTargets': 7}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.826 | Q17 | What gene does the drug Asciminib Hydrochloride target? | The drug Asciminib Hydrochloride targets 2 genes: BCR and ABL1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%asciminib hydrochloride%" OR LOWER(tradeNames_string) LIKE "%asciminib hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%asciminib hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4114', 'drugName': 'Asciminib Hydrochloride', 'tradeNames_string': 'Scemblix', 'drugSynonyms_string': 'ABL001-AAA, Asciminib hydrochloride, Scemblix', 'linkedDiseasesDrug_string': 'Chronic Myelogenous Leukemia (EFO_0000339)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), BCR (ENSG00000186716)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1143 | Q17 | What gene does the drug Insulin, Protamine Zinc target? | The drug Insulin, Protamine Zinc targets the gene INSR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%insulin, protamine zinc%" OR LOWER(tradeNames_string) LIKE "%insulin, protamine zinc%" OR LOWER(drugSynonyms_string) LIKE "%insulin, protamine zinc%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3652', 'drugName': 'Insulin, Protamine Zinc', 'tradeNames_string': 'Ins hypurin bov prot zn, Ins prot zn bp', 'drugSynonyms_string': 'Insulin zinc protamine injection (aqueous suspension), Insulin, protamine zinc, Protamine zinc insulin, Protamine zinc insulin injection', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.313 | Q17 | What gene does the drug Peginterferon Alfa-2B target? | The drug Peginterferon Alfa-2B targets 2 genes: IFNAR1 and IFNAR2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%peginterferon alfa-2b%" OR LOWER(tradeNames_string) LIKE "%peginterferon alfa-2b%" OR LOWER(drugSynonyms_string) LIKE "%peginterferon alfa-2b%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2953', 'drugName': 'Peginterferon Alfa-2B', 'tradeNames_string': 'Peg-Intron, Pegintron', 'drugSynonyms_string': 'Peg-interferon alfa-2b, Pegifn alfa-2b, Peginterferon alfa-2b, Peginterferon-alfa-2b, Pegylated interferon alpha 2b, Sylatron', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Primary Myelofibrosis (EFO_0002430), Essential Thrombocythemia (EFO_0000479), Metastatic Melanoma (EFO_0002617), Aids (EFO_0000765), Polycythemia Vera (EFO_0002429), Chronic Myelogenous Leukemia (EFO_0000339), Ovarian Cancer (MONDO_0008170), Lymphoid Neoplasm (EFO_0001642), Hepatitis C Virus Infection (EFO_0003047), Hepatocellular Carcinoma (EFO_0000182), Mantle Cell Lymphoma (EFO_1001469), Chronic Hepatitis B Virus Infection (EFO_0004239), Hepatitis D Virus Infection (EFO_0007304), Cholangiocarcinoma (EFO_0005221), Metastasis (EFO_0009708), Neurofibromatosis Type 1 (MONDO_0018975), Plexiform Neurofibroma (EFO_0000658), Renal Cell Carcinoma (EFO_0000681), Carcinoid Tumor (EFO_0004243), Peritoneum Cancer (MONDO_0002087), Chronic Hepatitis C Virus Infection (EFO_0004220), Glioma (EFO_0005543), Hiv-1 Infection (EFO_0000180), Skin Carcinoma (EFO_0009259), Craniopharyngioma (EFO_1000209), Cutaneous Melanoma (EFO_0000389), Cervical Cancer (MONDO_0002974), Pilocytic Astrocytoma (MONDO_0016691), Head And Neck Malignant Neoplasia (EFO_0006859), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Squamous Cell Carcinoma (EFO_0000707), Leukemia (EFO_0000565), Neoplasm (EFO_0000616), Hiv Infection (EFO_0000764), Hepatitis (HP_0012115), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Adult T-Cell Leukemia/Lymphoma (MONDO_0019471), Cirrhosis Of Liver (EFO_0001422)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'IFNAR1 (ENSG00000142166), IFNAR2 (ENSG00000159110)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5976', 'drugName': 'Ropeginterferon Alfa-2B', 'tradeNames_string': 'Besremi', 'drugSynonyms_string': 'Aop2014, Besremi, P-1101, P1101, Ropeginterferon alfa-2b, Ropeginterferon alfa-2b njft, Ropeginterferon alfa-2b-njft', 'linkedDiseasesDrug_string': 'Hepatocellular Carcinoma (EFO_0000182), Neoplasm (EFO_0000616), Chronic Hepatitis B Virus Infection (EFO_0004239), Essential Thrombocythemia (EFO_0000479), Hepatitis D Virus Infection (EFO_0007304), Chronic Hepatitis C Virus Infection (EFO_0004220), Polycythemia Vera (EFO_0002429), Chronic Myelogenous Leukemia (EFO_0000339)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'IFNAR1 (ENSG00000142166), IFNAR2 (ENSG00000159110)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.229 | Q17 | What gene does the drug Oncolysin Cd6 target? | The drug Oncolysin Cd6 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CD6. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%oncolysin cd6%" OR LOWER(tradeNames_string) LIKE "%oncolysin cd6%" OR LOWER(drugSynonyms_string) LIKE "%oncolysin cd6%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3220', 'drugName': 'Oncolysin Cd6', 'tradeNames_string': '', 'drugSynonyms_string': 'ONCOLYSIN CD6', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'CD6 (ENSG00000013725)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1699 | Q17 | What gene does the drug Gonadotropin, Chorionic target? | The drug Gonadotropin, Chorionic targets the gene LHCGR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%gonadotropin, chorionic%" OR LOWER(tradeNames_string) LIKE "%gonadotropin, chorionic%" OR LOWER(drugSynonyms_string) LIKE "%gonadotropin, chorionic%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3636', 'drugName': 'Gonadotropin, Chorionic', 'tradeNames_string': 'A.p.l., Choragon, Chorionic gonadotropin, Equine Chorionic Gonadotropin, Follutein, Gonadotraphon lh, Human Chorionic Gonadotropin, Pregnyl, Profasi, Profast, Progestyl', 'drugSynonyms_string': 'Choriogonadotropin beta, Chorionic gonadotrophin, Gonadotropin, chorionic', 'linkedDiseasesDrug_string': 'Hypogonadism (MONDO_0002146), Polycystic Ovary Syndrome (EFO_0000660), Breast Cancer (MONDO_0007254), Infertility (EFO_0000545), Azoospermia (EFO_0000279), Hypogonadotropic Hypogonadism (MONDO_0018555), Acute Graft Vs. Host Disease (EFO_0004599), Pregnancy (EFO_0002950), Gonadal Disorder (MONDO_0002259), Anovulation (MONDO_0002775)', 'yearOfFirstApproval': 1973, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'LHCGR (ENSG00000138039)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1451 | Q17 | What gene does the drug Trenonacog Alfa target? | The drug Trenonacog Alfa is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene F9. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%trenonacog alfa%" OR LOWER(tradeNames_string) LIKE "%trenonacog alfa%" OR LOWER(drugSynonyms_string) LIKE "%trenonacog alfa%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3960', 'drugName': 'Trenonacog Alfa', 'tradeNames_string': 'Ixinity[tm]', 'drugSynonyms_string': 'IB-1001, IB1001, Trenonacog alfa', 'linkedDiseasesDrug_string': 'Hemophilia B (MONDO_0010604), Sandhoff Disease (MONDO_0010006), Tay-Sachs Disease (MONDO_0010100), Niemann-Pick Disease Type C (MONDO_0018982), Ataxia Telangiectasia (MONDO_0008840)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'F9 (ENSG00000101981)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4764', 'drugName': 'Eftrenonacog Alfa', 'tradeNames_string': '', 'drugSynonyms_string': 'Alprolix, BIIB-029, Eftrenonacog alfa, Rfixfc', 'linkedDiseasesDrug_string': 'Hemophilia (MONDO_0018660), Hemophilia B (MONDO_0010604)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'F9 (ENSG00000101981)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1976 | Q17 | What gene does the drug Praliciguat target? | The drug Praliciguat is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 4 genes: GUCY1A1, GUCY1B2, GUCY1A2 and GUCY1B1 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%praliciguat%" OR LOWER(tradeNames_string) LIKE "%praliciguat%" OR LOWER(drugSynonyms_string) LIKE "%praliciguat%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_594', 'drugName': 'Praliciguat', 'tradeNames_string': '', 'drugSynonyms_string': 'IW-1973, Praliciguat', 'linkedDiseasesDrug_string': 'Heart Failure (EFO_0003144)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'GUCY1B1 (ENSG00000061918), GUCY1B2 (ENSG00000123201), GUCY1A2 (ENSG00000152402), GUCY1A1 (ENSG00000164116)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.814 | Q17 | What gene does the drug Metoprolol target? | The drug Metoprolol targets the gene ADRB1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%metoprolol%" OR LOWER(tradeNames_string) LIKE "%metoprolol%" OR LOWER(drugSynonyms_string) LIKE "%metoprolol%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1081', 'drugName': 'Metoprolol', 'tradeNames_string': '', 'drugSynonyms_string': '(rs)-metoprolol, Beatrolol, CGP-2175, Dl-metoprolol, Lopressidone, Metoprolol, Metoprolol slow release, Seroken, Toprol-XL', 'linkedDiseasesDrug_string': 'Psoriasis (EFO_0000676), Orthostatic Hypotension (EFO_0005252), Coronary Artery Disease (EFO_0001645), Non-St Elevation Myocardial Infarction (EFO_0008586), Obesity (EFO_0001073), St Elevation Myocardial Infarction (EFO_0008585), Prader-Willi Syndrome (MONDO_0008300), Malaria (EFO_0001068), Atrial Fibrillation (EFO_0000275), Congestive Heart Failure (EFO_0000373), Breast Cancer (MONDO_0007254), Angina Pectoris (EFO_0003913), Beta-Thalassemia (Orphanet_848), Atopic Eczema (EFO_0000274), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Ventricular Fibrillation (EFO_0004287), Fish-Eye Disease (Orphanet_79292), Acute Myocardial Infarction (EFO_0008583), Sudden Cardiac Arrest (EFO_0004278), Mitral Regurgitation (HP_0001653), Ventricular Tachycardia (EFO_0005306), Premature Birth (EFO_0003917), Aortic Stenosis (EFO_0000266), Stroke (EFO_0000712), Duchenne Muscular Dystrophy (MONDO_0010679), Chronic Obstructive Pulmonary Disease (EFO_0000341), Hypercholesterolemia (HP_0003124), Myocardial Infarction (EFO_0000612), Ventricular Arrhythmia (HP_0004308), Heart Disease (EFO_0003777), Hiv Infection (EFO_0000764), Neoplasm (EFO_0000616), Heart Failure (EFO_0003144), Hypertrophic Cardiomyopathy (EFO_0000538), Type 2 Diabetes Mellitus (MONDO_0005148), Atherosclerosis (EFO_0003914)', 'yearOfFirstApproval': 1978, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1301', 'drugName': 'Metoprolol Tartrate', 'tradeNames_string': 'Arbralene, Beloc cor, Betaloc, Betaloc s.a., Lopresor, Lopresor sr, Lopressor, Mepranix 100, Mepranix 50, Metoprolol tartrate, Tensomex, Toprol xl', 'drugSynonyms_string': 'Beloc, CGP-2175E, Metoprolol hemitartrate, Metoprolol tartrate, Metropress, NSC-757105, Prelis, Seloken, Selopral', 'linkedDiseasesDrug_string': 'Heart Disease (EFO_0003777), Angina Pectoris (EFO_0003913), Stroke (EFO_0000712), Heart Failure (EFO_0003144), Hypertension (EFO_0000537), Myocardial Infarction (EFO_0000612), Atrial Fibrillation (EFO_0000275)', 'yearOfFirstApproval': 1978, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3227', 'drugName': 'Metoprolol Fumarate', 'tradeNames_string': 'Lopressor, Metoros, Metoros ls', 'drugSynonyms_string': 'CGP 2175C, CGP-2175C, Metoprolol fumarate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1989, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2286', 'drugName': 'Metoprolol Succinate', 'tradeNames_string': 'Kapspargo sprinkle, Metoprolol succinate, Toprol, Toprol Xl, Toprol-xl', 'drugSynonyms_string': 'H 93/26 SUCCINATE, Metoprolol hemisuccinate, Metoprolol succinate, Seloken-zok, Selozok', 'linkedDiseasesDrug_string': 'Congestive Heart Failure (EFO_0000373), Angina Pectoris (EFO_0003913), Aortic Stenosis (EFO_0000266), Heart Failure (EFO_0003144), Duchenne Muscular Dystrophy (MONDO_0010679), Hypertension (EFO_0000537), Chronic Obstructive Pulmonary Disease (EFO_0000341), Fish-Eye Disease (Orphanet_79292), Hypertrophic Cardiomyopathy (EFO_0000538), Mitral Regurgitation (HP_0001653), Atrial Fibrillation (EFO_0000275)', 'yearOfFirstApproval': 1992, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1847 | Q17 | What gene does the drug Diazepam target? | The drug Diazepam targets 16 genes: GABRG2, GABRE, GABRA4, GABRQ, GABRD, GABRA3, GABRP, GABRA5, GABRG3, GABRB2, GABRB3, GABRG1, GABRA2, GABRB1, GABRA6 and GABRA1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%diazepam%" OR LOWER(tradeNames_string) LIKE "%diazepam%" OR LOWER(drugSynonyms_string) LIKE "%diazepam%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1439', 'drugName': 'Diazepam', 'tradeNames_string': 'Alupram 10, Alupram 2, Alupram 5, Apozepam, Atensine, Dialar, Dialar fte, Diastat, Diastat acudial, Diazepam, Diazepam intensol, Dizac, E-Pam, Paxel, Q-pam, Relanium, Scriptopam, Serenack, Solis, Stesolid, Tensium, Tranimul, Valclair, Valium, Valrelease, Valtoco, Vivol', 'drugSynonyms_string': 'Ansiolisina, Centrazepam, Diacepin, Diazepam, Diazepam civ, LA III, LA-III, NRL-1, NSC-169897, NSC-77518, Nrl-1, RO 5-2807, RO-5-2807, RO-52807, Servizepam, Tranquase, WY-3467', 'linkedDiseasesDrug_string': 'Cerebral Palsy (EFO_1000632), Anxiety Disorder (EFO_0006788), Rotator Cuff Tear (EFO_1001250), Pain (EFO_0003843), Agitation (HP_0000713), Stiff-Person Syndrome (EFO_0007498), Dementia (HP_0000726), Landau-Kleffner Syndrome (EFO_1001010), Anxiety (EFO_0005230), Complex Partial Epilepsy (EFO_1000877), Epilepsy (EFO_0000474), Low Back Pain (HP_0003419), Seizure (HP_0001250), Depressive Disorder (MONDO_0002050), Status Epilepticus (EFO_0008526), Schizophrenia (MONDO_0005090), Injury (EFO_0000546)', 'yearOfFirstApproval': 1963, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 16}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.151 | Q17 | What gene does the drug Nebicapone target? | The drug Nebicapone is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene COMT. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%nebicapone%" OR LOWER(tradeNames_string) LIKE "%nebicapone%" OR LOWER(drugSynonyms_string) LIKE "%nebicapone%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1116', 'drugName': 'Nebicapone', 'tradeNames_string': '', 'drugSynonyms_string': 'Nebicapone', 'linkedDiseasesDrug_string': 'Parkinson Disease (MONDO_0005180)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'COMT (ENSG00000093010)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.781 | Q17 | What gene does the drug Lanatoside C target? | The drug Lanatoside C targets 8 genes: ATP1B1, ATP1A3, ATP1A2, ATP1A4, FXYD2, ATP1A1, ATP1B3 and ATP1B2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lanatoside c%" OR LOWER(tradeNames_string) LIKE "%lanatoside c%" OR LOWER(drugSynonyms_string) LIKE "%lanatoside c%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2987', 'drugName': 'Lanatoside C', 'tradeNames_string': 'Cedilanid', 'drugSynonyms_string': 'Allocor, Celadigal, Cetosanol, Digilanogen c, Isolanid, Isolanide, Lanatigen c, Lanatoside c, Lanatoside c jp 17, Lanimerck, NSC-119991, NSC-7533', 'linkedDiseasesDrug_string': 'Cardiovascular Disease (EFO_0000319)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ATP1A1 (ENSG00000163399), ATP1B2 (ENSG00000129244), ATP1B1 (ENSG00000143153), ATP1A2 (ENSG00000018625), ATP1B3 (ENSG00000069849), ATP1A3 (ENSG00000105409), ATP1A4 (ENSG00000132681), FXYD2 (ENSG00000137731)', 'numberLinkedTargets': 8}, {'UUID': 'DrugGeneTargets_v2_1509', 'drugName': 'Deslanoside', 'tradeNames_string': 'Cedilanid-d', 'drugSynonyms_string': 'Deacetylanatoside c, Desacetyl-lanatoside c, Deslanoside', 'linkedDiseasesDrug_string': 'Cardiovascular Disease (EFO_0000319)', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ATP1A1 (ENSG00000163399), ATP1B2 (ENSG00000129244), ATP1B1 (ENSG00000143153), ATP1A2 (ENSG00000018625), ATP1B3 (ENSG00000069849), ATP1A3 (ENSG00000105409), ATP1A4 (ENSG00000132681), FXYD2 (ENSG00000137731)', 'numberLinkedTargets': 8}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.727 | Q17 | What gene does the drug Teprotumumab target? | The drug Teprotumumab targets the gene IGF1R. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%teprotumumab%" OR LOWER(tradeNames_string) LIKE "%teprotumumab%" OR LOWER(drugSynonyms_string) LIKE "%teprotumumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1336', 'drugName': 'Teprotumumab', 'tradeNames_string': 'Tepezza', 'drugSynonyms_string': 'Onilcamotide, R-1507, RG-1507, RG1507, RO-4858696, RO-4858696-000, RO-4858696000, RO4858696, RO4858696-000, RV-001, RV-001 MONOCLONAL, RV001, RV001 MONOCLONAL, Rhoc peptide vaccine rv001v, Tepezza, Teprotumumab, Teprotumumab trbw, Teprotumumab-trbw', 'linkedDiseasesDrug_string': 'Graves Ophthalmopathy (EFO_1001466), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Sarcoma (EFO_0000691), Immune System Disease (EFO_0000540), Diffuse Scleroderma (EFO_0000404)', 'yearOfFirstApproval': 2020, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'IGF1R (ENSG00000140443)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.820 | Q17 | What gene does the drug Evolocumab target? | The drug Evolocumab targets the gene PCSK9. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%evolocumab%" OR LOWER(tradeNames_string) LIKE "%evolocumab%" OR LOWER(drugSynonyms_string) LIKE "%evolocumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_646', 'drugName': 'Evolocumab', 'tradeNames_string': 'Repatha, Repatha sureclick', 'drugSynonyms_string': 'AMG-145, Evolocumab', 'linkedDiseasesDrug_string': 'Hyperlipidemia (MONDO_0021187), Coronary Artery Disease (EFO_0001645), Sepsis (HP_0100806), Lung Cancer (MONDO_0008903), Stroke (EFO_0000712), Heart Failure (EFO_0003144), Non-Small Cell Lung Carcinoma (EFO_0003060), Combined Hyperlipidemia (Orphanet_79211), Cardiovascular Disease (EFO_0000319), Hypercholesterolemia (HP_0003124), Covid-19 (MONDO_0100096), Myocardial Infarction (EFO_0000612), Acute Coronary Syndrome (EFO_0005672), Homozygous Familial Hypercholesterolemia (MONDO_0018328), St Elevation Myocardial Infarction (EFO_0008585), Familial Hypercholesterolemia (EFO_0004911), Disorder Of Lipid Metabolism (Orphanet_309005), Glioblastoma Multiforme (EFO_0000519)', 'yearOfFirstApproval': 2015, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PCSK9 (ENSG00000169174)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1636 | Q17 | What gene does the drug Liraglutide target? | The drug Liraglutide targets the gene GLP1R. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%liraglutide%" OR LOWER(tradeNames_string) LIKE "%liraglutide%" OR LOWER(drugSynonyms_string) LIKE "%liraglutide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5245', 'drugName': 'Liraglutide', 'tradeNames_string': 'Saxenda, Victoza', 'drugSynonyms_string': 'Liraglutide, Liraglutide (rdna origin), Liraglutide recombinant, NN-2211, NN-9924, NN2211, NN9924, NNC 90-1170, NNC-90-1170', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Alzheimer Disease (MONDO_0004975), Obesity (EFO_0001073), Eating Disorder (EFO_0005203), Hyperglycemia (HP_0003074), Non-Alcoholic Steatohepatitis (EFO_1001249), Parkinson Disease (MONDO_0005180), Pouchitis (EFO_0003921), Abnormal Glucose Tolerance (EFO_0002546), Bipolar Disorder (MONDO_0004985), Opioid Dependence (EFO_0005611), Short Bowel Syndrome (MONDO_0015183), Smoking Cessation (EFO_0004319), Sleep Apnea (EFO_0003877), Diabetic Nephropathy (EFO_0000401), Mody (Orphanet_552), Heart Failure (EFO_0003144), Weight Loss (HP_0001824), Metabolic Syndrome (EFO_0000195), Prediabetes Syndrome (EFO_1001121), Major Depressive Disorder (MONDO_0002009), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148)', 'yearOfFirstApproval': 2010, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GLP1R (ENSG00000112164)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.825 | Q17 | What gene does the drug Sutimlimab target? | The drug Sutimlimab targets the gene C1S. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%sutimlimab%" OR LOWER(tradeNames_string) LIKE "%sutimlimab%" OR LOWER(drugSynonyms_string) LIKE "%sutimlimab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3495', 'drugName': 'Sutimlimab', 'tradeNames_string': 'Enjaymo', 'drugSynonyms_string': 'BIVV009, Bivv-009, Enjaymo, Sutimlimab, Sutimlimab jome, Sutimlimab-jome, TNT-009, TNT009', 'linkedDiseasesDrug_string': 'Autoimmune Thrombocytopenic Purpura (EFO_0007160), Immune System Disease (EFO_0000540), Anemia, Hemolytic, Autoimmune (EFO_1001264)', 'yearOfFirstApproval': 2022, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'C1S (ENSG00000182326)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.581 | Q17 | What gene does the drug Bevacizumab target? | The drug Bevacizumab targets the gene VEGFA. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bevacizumab%" OR LOWER(tradeNames_string) LIKE "%bevacizumab%" OR LOWER(drugSynonyms_string) LIKE "%bevacizumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_958', 'drugName': 'Bevacizumab', 'tradeNames_string': 'Avastin', 'drugSynonyms_string': '12-IGG1, AVA-1, Abp-215, Alymsys, BAT-1706, BI 695502, BI695502, BS-503A, Bat 1706, Bat1706, Bevacizumab, Bevacizumab awwb, Bevacizumab beta, Bevacizumab biosimilar (fkb-238), Bevacizumab bvzr, Bevacizumab maly, Bevacizumab-awwb, Bevacizumab-bvzr, Bevacizumab-maly, Bi-695502, Bs-503, Byvasda, CHS-5217, CT-16, CT-P16, CT-P16 (BIOSIMILAR OF BEVACIZUMAB), Ct-16, Ct-p16, FKB-238, Fkb 238, Fkb238, HLX-04, HLX04, Hlx 04, Ibi-305, Ibi305, LY 01008, LY-01008, Mvasi, PF-06439535, Pf-06439535, Q-1101, Q1101, R-435, RG-435, RHUMAB-, RHUMAB-VEGF, Usp mab 002, monoclonal igg1, Zirabev', 'linkedDiseasesDrug_string': "Ovarian Carcinoma (EFO_0001075), Clear Cell Adenocarcinoma (EFO_0000348), Multiple Myeloma (EFO_0001378), Oligodendroglioma (EFO_0000632), Wet Macular Degeneration (EFO_0004683), Hereditary Hemorrhagic Telangiectasia (MONDO_0019180), Malignant Colon Neoplasm (MONDO_0021063), Cervical Adenocarcinoma (EFO_0001416), Papillary Renal Cell Carcinoma (EFO_0000640), Primary Brain Neoplasm (MONDO_0021632), Liver Neoplasm (EFO_1001513), Pineoblastoma (EFO_1000475), Chromophobe Renal Cell Carcinoma (EFO_0000335), Liposarcoma (EFO_0000569), Signet Ring Cell Carcinoma (EFO_0000698), Malignant Glioma (MONDO_0100342), Inflammatory Breast Carcinoma (EFO_1000984), Retinopathy Of Prematurity (EFO_1001158), Neuroendocrine Neoplasm (EFO_1001901), Lung Adenocarcinoma (EFO_0000571), Pharynx Cancer (EFO_0005577), Undifferentiated Carcinoma (EFO_0006772), Clear Cell Renal Carcinoma (EFO_0000349), Pulmonary Venoocclusive Disease (MONDO_0009937), Brain Neoplasm (EFO_0003833), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Fibrosarcoma (EFO_0002087), Carcinoma (EFO_0000313), Pterygium (EFO_0000678), Liver Cancer (MONDO_0002691), Cervical Cancer (MONDO_0002974), Choroiditis (MONDO_0001280), Follicular Lymphoma (MONDO_0018906), Ewing Sarcoma (EFO_0000174), Lung Cancer (MONDO_0008903), Diabetic Neuropathy (EFO_1000783), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Leukemia (EFO_0000565), Colorectal Adenocarcinoma (EFO_0000365), Leiomyosarcoma (EFO_0000564), Malignant Pleural Mesothelioma (EFO_0000770), Glioblastoma Multiforme (EFO_0000519), Germ Cell Tumor (EFO_0000514), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Myopia (HP_0000545), Hemorrhage (MP_0001914), Neuromyelitis Optica (EFO_0004256), Gastrointestinal Stromal Tumor (MONDO_0011719), Central Nervous System Cancer (EFO_0000326), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Retinopathy (EFO_0003839), Coronavirus Infectious Disease (EFO_0007224), Angiosarcoma (EFO_0003968), Neuroendocrine Carcinoma (MONDO_0002120), Uveitis (EFO_1001231), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Fallopian Tube Carcinoma (EFO_1000251), Mantle Cell Lymphoma (EFO_1001469), Gastric Adenocarcinoma (EFO_0000503), Diabetic Retinopathy (EFO_0003770), Myelofibrosis (MONDO_0044903), Endometriosis (EFO_0001065), Diffuse Large B-Cell Lymphoma (EFO_0000403), Gastric Carcinoma (EFO_0000178), Metastasis (EFO_0009708), Vitreous Hemorrhage (EFO_0008626), Anaplastic Oligodendroglioma (EFO_0002501), Small Cell Lung Carcinoma (EFO_0000702), Triple-Negative Breast Cancer (EFO_0005537), Thyroid Cancer (MONDO_0002108), Large Cell Lung Carcinoma (EFO_0003050), Choriocarcinoma (EFO_0002893), Malignant Peripheral Nerve Sheath Tumor (EFO_0000760), Hodgkins Lymphoma (EFO_0000183), Rectum Cancer (EFO_1000657), Chronic Kidney Disease (EFO_0003884), Merkel Cell Skin Cancer (EFO_1001471), Myeloproliferative Disorder (EFO_0004251), Non-Small Cell Lung Carcinoma (EFO_0003060), Colonic Neoplasm (EFO_0004288), Corneal Neovascularization (EFO_1000880), Vascular Disease (EFO_0004264), Aseptic Meningitis (EFO_1000823), Peripheral Primitive Neuroectodermal Tumor (MONDO_0018271), Neuroblastoma (EFO_0000621), Lymphedema (MONDO_0019297), Retinal Vein Occlusion (EFO_1001157), Somatostatinoma (EFO_1001187), Sex Cord-Stromal Tumor (EFO_1000052), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Urothelial Carcinoma (EFO_0008528), Intrahepatic Cholangiocarcinoma (EFO_1001961), Pancreatic Insulinoma (MONDO_0024677), Glaucoma (MONDO_0005041), Esophageal Carcinoma (EFO_0002916), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Gastrointestinal Disease (EFO_0010282), Anaplastic Astrocytoma (EFO_0002499), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Anaplastic Ependymoma (MONDO_0016700), Lymphoma (EFO_0000574), Ocular Vascular Disease (EFO_0005753), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Pleural Effusion (EFO_0009637), Biliary Tract Cancer (MONDO_0003060), Cholangiocarcinoma (EFO_0005221), Keloid (EFO_0004212), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Rhabdomyosarcoma (EFO_0002918), Lynch Syndrome (MONDO_0005835), Colorectal Cancer (MONDO_0005575), Neoplasm Of Mature B-Cells (EFO_0000096), Central Serous Retinopathy (EFO_0009784), Mesothelioma (EFO_0000588), Carcinoid Tumor (EFO_0004243), Adenoma (EFO_0000232), Peritoneum Cancer (MONDO_0002087), Glioma (EFO_0005543), Brain Injury (MONDO_0043510), Papilloma (MONDO_0002363), Cutaneous Melanoma (EFO_0000389), Age-Related Macular Degeneration (EFO_0001365), Thymoma (EFO_1000581), Neoplasm (EFO_0000616), Ovarian Serous Cystadenocarcinoma (EFO_1000043), Urinary Bladder Cancer (MONDO_0001187), Adenocarcinoma (EFO_0000228), Uterine Carcinosarcoma (EFO_1000613), Metastatic Prostate Cancer (EFO_0000196), Sarcoma (EFO_0000691), Colon Adenocarcinoma (EFO_1001949), Synovial Sarcoma (EFO_0001376), Pulmonary Fibrosis (EFO_0009448), Alveolar Soft Part Sarcoma (EFO_0007143), Von Hippel-Lindau Disease (MONDO_0008667), Telangiectasis (MONDO_0001576), Grade Iii Meningioma (MONDO_0020634), Macular Degeneration (EFO_0009606), Medulloblastoma (EFO_0002939), Pneumonia (EFO_0003106), Thyroid Carcinoma (EFO_0002892), Mixed Glioma (MONDO_0003268), Covid-19 (MONDO_0100096), Peritoneal Neoplasm (EFO_1001100), Metastatic Melanoma (EFO_0002617), Collecting Duct Carcinoma (EFO_0003016), Endometrial Cancer (MONDO_0011962), Desmoplastic Small Round Cell Tumor (EFO_1000895), Rectal Carcinoma (MONDO_0044937), Chronic Myelogenous Leukemia (EFO_0000339), Retinal Detachment (EFO_0005773), Ascites (HP_0001541), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305), Astrocytoma (EFO_0000272), Anterior Ischemic Optic Neuropathy (EFO_1000809), Prostate Cancer (MONDO_0008315), Oligoastrocytoma (EFO_0000630), Malignant Peritoneal Mesothelioma (EFO_0005567), Colorectal Neoplasm (EFO_0004142), Male Breast Carcinoma (EFO_0006861), Cervical Carcinoma (EFO_0001061), Placental Site Trophoblastic Tumor (EFO_1001111), Benign Fibrous Histiocytoma (MONDO_0002989), Endometrial Carcinoma (EFO_1001512), Esophageal Cancer (MONDO_0007576), Extranodal Nasal Nk/T Cell Lymphoma (MONDO_0019472), Spinal Cord Neoplasm (EFO_0003828), Alveolar Rhabdomyosarcoma (EFO_0000248), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Inflammation (MP_0001845), Ependymoma (EFO_1000028), Cystoid Macular Edema (MONDO_0007935), Schwannoma (EFO_0000693), Ovarian Neoplasm (EFO_0003893), Endometrioid Carcinoma (EFO_0000466), Macular Retinal Edema (MONDO_0003005), Brain Cancer (MONDO_0001657), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Squamous Cell Carcinoma (EFO_0000707), Vogt-Koyanagi-Harada Disease (MONDO_0018092), Meningioma (MONDO_0016642), Nasopharyngeal Neoplasm (EFO_0004252), Adrenal Cortex Carcinoma (EFO_1000796), Kaposi'S Sarcoma (EFO_0000558), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Severe Acute Respiratory Syndrome (EFO_0000694), Pancreatic Neoplasm (EFO_0003860), Pancreatic Endocrine Carcinoma (EFO_0007416)", 'yearOfFirstApproval': 2004, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'VEGFA (ENSG00000112715)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1618', 'drugName': 'Bevacizumab 111In', 'tradeNames_string': '', 'drugSynonyms_string': 'Bevacizumab 111in, Bevacizumab in111', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': -1, 'drugIsApproved': False, 'newLinkedTargets_string': 'VEGFA (ENSG00000112715)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.563 | Q17 | What gene does the drug Butabarbital target? | The drug Butabarbital targets 16 genes: GABRG2, GABRE, GABRA4, GABRQ, GABRD, GABRA3, GABRP, GABRA5, GABRG3, GABRB2, GABRB3, GABRG1, GABRA2, GABRB1, GABRA6 and GABRA1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%butabarbital%" OR LOWER(tradeNames_string) LIKE "%butabarbital%" OR LOWER(drugSynonyms_string) LIKE "%butabarbital%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_422', 'drugName': 'Butabarbital', 'tradeNames_string': '', 'drugSynonyms_string': 'Butabarbital, Butabarbital ciii, Butatab, Medarsed, Nilox, Sec-butobarbitone, Secbutabarbital, Secbutobarbitone, Unicelles', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1939, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 16}, {'UUID': 'DrugGeneTargets_v2_3050', 'drugName': 'Butabarbital Sodium', 'tradeNames_string': 'Butabarb, Butabarbital, Butabarbital sodium, Butalan, Buticaps, Butisol sodium, Sarisol, Sarisol no. 1, Sarisol no. 2, Sodium butabarbital', 'drugSynonyms_string': 'Astrudion, Butabarbital sodium, Butabarbital sodium salt, Loubarb, Mebutal, NSC-11778, Secbutabarbital sodium', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1939, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 16}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1758 | Q17 | What gene does the drug Mepenzolate target? | The drug Mepenzolate targets 2 genes: CHRM1 and CHRM3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%mepenzolate%" OR LOWER(tradeNames_string) LIKE "%mepenzolate%" OR LOWER(drugSynonyms_string) LIKE "%mepenzolate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3596', 'drugName': 'Mepenzolate', 'tradeNames_string': '', 'drugSynonyms_string': 'Mepenzolate, Mepenzolate bromide free base, Mepenzolate cation, Mepenzolate ion', 'linkedDiseasesDrug_string': 'Gastrointestinal Disease (EFO_0010282)', 'yearOfFirstApproval': 1956, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM1 (ENSG00000168539)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3595', 'drugName': 'Mepenzolate', 'tradeNames_string': '', 'drugSynonyms_string': 'Mepenzolate, Mepenzolate bromide free base, Mepenzolate cation, Mepenzolate ion', 'linkedDiseasesDrug_string': 'Gastrointestinal Disease (EFO_0010282)', 'yearOfFirstApproval': 1956, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM1 (ENSG00000168539)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1923', 'drugName': 'Mepenzolate Bromide', 'tradeNames_string': 'Cantil', 'drugSynonyms_string': 'AN-6437, FT-0671006, Glycophenylate, HY-17585, Mepenzolate, Mepenzolate Bromide, Mepenzolate bromide, Mepenzolate methylbromide, Mepenzolone bromide, NSC-4358', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1956, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM1 (ENSG00000168539)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1922', 'drugName': 'Mepenzolate Bromide', 'tradeNames_string': 'Cantil', 'drugSynonyms_string': 'AN-6437, FT-0671006, Glycophenylate, HY-17585, Mepenzolate, Mepenzolate Bromide, Mepenzolate bromide, Mepenzolate methylbromide, Mepenzolone bromide, NSC-4358', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1956, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM1 (ENSG00000168539)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1727 | Q17 | What gene does the drug Danazol target? | The drug Danazol targets 2 genes: PGR and AR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%danazol%" OR LOWER(tradeNames_string) LIKE "%danazol%" OR LOWER(drugSynonyms_string) LIKE "%danazol%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4916', 'drugName': 'Danazol', 'tradeNames_string': 'Danazol, Danocrine', 'drugSynonyms_string': 'Danazol, NSC-270916, WIN 17,757, WIN-17757', 'linkedDiseasesDrug_string': 'Fanconi Anemia (MONDO_0019391), Autoimmune Thrombocytopenic Purpura (EFO_0007160), Infertility (EFO_0000545), Mastodynia (EFO_1001366), Endometriosis (EFO_0001065), Aplastic Anemia (HP_0001915), Dyskeratosis Congenita (MONDO_0015780), Endometrial Cancer (MONDO_0011962), Thrombotic Thrombocytopenic Purpura (MONDO_0018896), Breast Fibrocystic Disease (EFO_0003014), Myelodysplastic Syndrome (EFO_0000198), Autoimmune Thrombocytopenia (MONDO_0019098)', 'yearOfFirstApproval': 1976, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083), PGR (ENSG00000082175)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4917', 'drugName': 'Danazol', 'tradeNames_string': 'Danazol, Danocrine', 'drugSynonyms_string': 'Danazol, NSC-270916, WIN 17,757, WIN-17757', 'linkedDiseasesDrug_string': 'Fanconi Anemia (MONDO_0019391), Autoimmune Thrombocytopenic Purpura (EFO_0007160), Infertility (EFO_0000545), Mastodynia (EFO_1001366), Endometriosis (EFO_0001065), Aplastic Anemia (HP_0001915), Dyskeratosis Congenita (MONDO_0015780), Endometrial Cancer (MONDO_0011962), Thrombotic Thrombocytopenic Purpura (MONDO_0018896), Breast Fibrocystic Disease (EFO_0003014), Myelodysplastic Syndrome (EFO_0000198), Autoimmune Thrombocytopenia (MONDO_0019098)', 'yearOfFirstApproval': 1976, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083), PGR (ENSG00000082175)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1349 | Q17 | What gene does the drug Rabeprazole target? | The drug Rabeprazole targets 2 genes: ATP4B and ATP4A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%rabeprazole%" OR LOWER(tradeNames_string) LIKE "%rabeprazole%" OR LOWER(drugSynonyms_string) LIKE "%rabeprazole%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5144', 'drugName': 'Rabeprazole Sodium', 'tradeNames_string': 'Aciphex, Aciphex sprinkle, Pariet, Rabeprazole sodium', 'drugSynonyms_string': 'E-3810, E-3810 SODIUM, Idiazole, LY-307640, LY-307640 SODIUM, LY307640 SODIUM, NSC-759270, Rabeprazole na, Rabeprazole sodium, Rabeprazole sodium salt, Sodium rabeprazole', 'linkedDiseasesDrug_string': 'Laryngopharyngeal Reflux (EFO_1001355), Duodenal Ulcer (EFO_0004607), Zollinger-Ellison Syndrome (EFO_0007549), Cerebrovascular Disorder (EFO_0003763), Peptic Esophagitis (EFO_1001095), Gastroesophageal Reflux Disease (EFO_0003948)', 'yearOfFirstApproval': 1999, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ATP4A (ENSG00000105675), ATP4B (ENSG00000186009)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3572', 'drugName': 'Rabeprazole', 'tradeNames_string': '', 'drugSynonyms_string': 'Aciphex, E-3810 (PPI), E3810, Eraloc, LY-307640, LY307640, Ly-307640, Pariprazole, Rabeprazole', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Amyotrophic Lateral Sclerosis (MONDO_0004976), Peptic Ulcer (HP_0004398), Gastrointestinal Hemorrhage (HP_0002239), Infectious Disease (EFO_0005741), Dyspepsia (EFO_0008533), Laryngopharyngeal Reflux (EFO_1001355), Duodenal Ulcer (EFO_0004607), Zollinger-Ellison Syndrome (EFO_0007549), Cerebrovascular Disorder (EFO_0003763), Helicobacter Pylori Infectious Disease (EFO_1000961), Peptic Esophagitis (EFO_1001095), Gastroesophageal Reflux Disease (EFO_0003948), Lymphoid Neoplasm (EFO_0001642)', 'yearOfFirstApproval': 1999, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ATP4A (ENSG00000105675), ATP4B (ENSG00000186009)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1161 | Q17 | What gene does the drug Unasnemab target? | The drug Unasnemab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene RGMA. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%unasnemab%" OR LOWER(tradeNames_string) LIKE "%unasnemab%" OR LOWER(drugSynonyms_string) LIKE "%unasnemab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4076', 'drugName': 'Unasnemab', 'tradeNames_string': '', 'drugSynonyms_string': 'MT-3921, MT3921, Mt-3921, Unasnemab', 'linkedDiseasesDrug_string': 'Spinal Cord Injury (EFO_1001919)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'RGMA (ENSG00000182175)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.945 | Q17 | What gene does the drug Carphenazine Maleate target? | The drug Carphenazine Maleate targets 3 genes: HTR2C, HTR2A and DRD2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%carphenazine maleate%" OR LOWER(tradeNames_string) LIKE "%carphenazine maleate%" OR LOWER(drugSynonyms_string) LIKE "%carphenazine maleate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3158', 'drugName': 'Carphenazine Maleate', 'tradeNames_string': 'Proketazine', 'drugSynonyms_string': 'Carfenazine maleate, Carphenazine, Carphenazine dimaleate, Carphenazine maleate, NSC-71755, WY-2445', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2C (ENSG00000147246), DRD2 (ENSG00000149295), HTR2A (ENSG00000102468)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_3159', 'drugName': 'Carphenazine Maleate', 'tradeNames_string': 'Proketazine', 'drugSynonyms_string': 'Carfenazine maleate, Carphenazine, Carphenazine dimaleate, Carphenazine maleate, NSC-71755, WY-2445', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2C (ENSG00000147246), DRD2 (ENSG00000149295), HTR2A (ENSG00000102468)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_3160', 'drugName': 'Carphenazine Maleate', 'tradeNames_string': 'Proketazine', 'drugSynonyms_string': 'Carfenazine maleate, Carphenazine, Carphenazine dimaleate, Carphenazine maleate, NSC-71755, WY-2445', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2C (ENSG00000147246), DRD2 (ENSG00000149295), HTR2A (ENSG00000102468)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.290 | Q17 | What gene does the drug Hexocyclium target? | The drug Hexocyclium targets 2 genes: CHRM3 and CHRM1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%hexocyclium%" OR LOWER(tradeNames_string) LIKE "%hexocyclium%" OR LOWER(drugSynonyms_string) LIKE "%hexocyclium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3245', 'drugName': 'Hexocyclium', 'tradeNames_string': '', 'drugSynonyms_string': 'Hexocyclium, Hexocyclium cation, Hexocyclium ion', 'linkedDiseasesDrug_string': 'Gastrointestinal Disease (EFO_0010282)', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM1 (ENSG00000168539), CHRM3 (ENSG00000133019)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3244', 'drugName': 'Hexocyclium', 'tradeNames_string': '', 'drugSynonyms_string': 'Hexocyclium, Hexocyclium cation, Hexocyclium ion', 'linkedDiseasesDrug_string': 'Gastrointestinal Disease (EFO_0010282)', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM1 (ENSG00000168539), CHRM3 (ENSG00000133019)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_2266', 'drugName': 'Hexocyclium Methylsulfate', 'tradeNames_string': 'Tral', 'drugSynonyms_string': 'Hexocyclium methyl sulfate, Hexocyclium methylsulfate, Hexocyclium methylsulphate, Hexocyclium metilsulfate, Hexocyclium metilsulphate, NSC-30256', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM1 (ENSG00000168539), CHRM3 (ENSG00000133019)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_2265', 'drugName': 'Hexocyclium Methylsulfate', 'tradeNames_string': 'Tral', 'drugSynonyms_string': 'Hexocyclium methyl sulfate, Hexocyclium methylsulfate, Hexocyclium methylsulphate, Hexocyclium metilsulfate, Hexocyclium metilsulphate, NSC-30256', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM1 (ENSG00000168539), CHRM3 (ENSG00000133019)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1947 | Q17 | What gene does the drug Lebrikizumab target? | The drug Lebrikizumab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene IL13. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lebrikizumab%" OR LOWER(tradeNames_string) LIKE "%lebrikizumab%" OR LOWER(drugSynonyms_string) LIKE "%lebrikizumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2381', 'drugName': 'Lebrikizumab', 'tradeNames_string': '', 'drugSynonyms_string': 'Lebrikizumab, MILR-1444A, MILR1444A, PRO-301444, PRO-301444 RG-3637, PRO301444, RG-3637', 'linkedDiseasesDrug_string': 'Idiopathic Pulmonary Fibrosis (EFO_0000768), Asthma (MONDO_0004979), Atopic Eczema (EFO_0000274), Chronic Obstructive Pulmonary Disease (EFO_0000341)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'IL13 (ENSG00000169194)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.973 | Q17 | What gene does the drug Indomethacin target? | The drug Indomethacin targets 2 genes: PTGS2 and PTGS1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%indomethacin%" OR LOWER(tradeNames_string) LIKE "%indomethacin%" OR LOWER(drugSynonyms_string) LIKE "%indomethacin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3165', 'drugName': 'Indomethacin', 'tradeNames_string': 'Artracin, Artracin sr, Berlind 75 ret, Flexin-25 continus, Flexin-50 continus, Flexin-75 continus, Imbrilon, Indo-lemmon, Indo-paed, Indocid ret, Indocid-r, Indocin, Indocin sr, Indoderm, Indoflex, Indolar, Indolar sr, Indomax-25, Indomax-75 sr, Indomethacin, Indomod, Indoptol, Indotard mr 75, Ledmecin, Maximet sr, Mobilan, Pardelprin mr, Rheumacin la, Rimacid, Slo-indo, Tivorbex', 'drugSynonyms_string': 'Aconip, Durametacin, Indometacin, Indometacin farnesil, Indometacinum, Indomethacin, NSC-757061, NSC-77541, Reumacide', 'linkedDiseasesDrug_string': 'Toothache (EFO_0010072), Alzheimer Disease (MONDO_0004975), Rheumatic Disease (EFO_0005755), Langerhans Cell Histiocytosis (EFO_1000318), Orthostatic Hypotension (EFO_0005252), Ankylosing Spondylitis (EFO_0003898), Hemorrhage (MP_0001914), Pain (EFO_0003843), Covid-19 (MONDO_0100096), Prostate Adenocarcinoma (EFO_0000673), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Eye Inflammation (EFO_0005752), Cardiovascular Disease (EFO_0000319), Fish-Eye Disease (Orphanet_79292), Oral Squamous Cell Carcinoma (EFO_0000199), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Acute Pancreatitis (EFO_1000652), Chronic Pancreatitis (EFO_0000342), Patent Ductus Arteriosus (HP_0001643), Asthma (MONDO_0004979), Premature Birth (EFO_0003917), Renal Colic (EFO_1001412), Inflammation (MP_0001845), Rheumatoid Arthritis (EFO_0000685), Cutaneous Melanoma (EFO_0000389), Myalgia (HP_0003326), Gout (EFO_0004274), Pancreatitis (EFO_0000278), Osteoarthritis (MONDO_0005178), Arthralgia (HP_0002829), Metastatic Prostate Cancer (EFO_0000196), Squamous Cell Intraepithelial Neoplasia (MONDO_0024475), Spondylitis (MONDO_0003937)', 'yearOfFirstApproval': 1965, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4252', 'drugName': 'Indomethacin Sodium', 'tradeNames_string': 'Indocin, Indomethacin sodium', 'drugSynonyms_string': 'Indometacin sodium, Indometacin sodium hydrate, Indometacin sodium trihydrate, Indomethacin sodium, Indomethacin sodium anhydrous, Indomethacin sodium salt trihydrate, Indomethacin sodium trihydrate, Sodium indomethacin, Sodium indomethacin trihydrate', 'linkedDiseasesDrug_string': 'Inflammation (MP_0001845)', 'yearOfFirstApproval': 1985, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.605 | Q17 | What gene does the drug Capmatinib target? | The drug Capmatinib targets the gene MET. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%capmatinib%" OR LOWER(tradeNames_string) LIKE "%capmatinib%" OR LOWER(drugSynonyms_string) LIKE "%capmatinib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_910', 'drugName': 'Capmatinib', 'tradeNames_string': '', 'drugSynonyms_string': 'Capmatinib, INC-280, INC280, INCB-28060, INCB-28060 FREE BASE, Incb-28060, NVP-INC280, NVP-INC280-NX, NYP-INC280-NX', 'linkedDiseasesDrug_string': 'Hepatocellular Carcinoma (EFO_0000182), Breast Cancer (MONDO_0007254), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Liver Disease (EFO_0001421), Non-Small Cell Lung Carcinoma (EFO_0003060), Kidney Cancer (MONDO_0002367), Soft Tissue Sarcoma (EFO_1001968), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519), Cutaneous Melanoma (EFO_0000389)', 'yearOfFirstApproval': 2020, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MET (ENSG00000105976)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_568', 'drugName': 'Capmatinib Hydrochloride', 'tradeNames_string': 'Tabrecta', 'drugSynonyms_string': 'Capmatinib hydrochloride, Capmatinib hydrochloride hydrate, NVP-INC280-AAA', 'linkedDiseasesDrug_string': 'Non-Small Cell Lung Carcinoma (EFO_0003060)', 'yearOfFirstApproval': 2020, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MET (ENSG00000105976)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1312 | Q17 | What gene does the drug Fe 202767 target? | The drug Fe 202767 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene OXTR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fe 202767%" OR LOWER(tradeNames_string) LIKE "%fe 202767%" OR LOWER(drugSynonyms_string) LIKE "%fe 202767%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1641', 'drugName': 'Fe 202767', 'tradeNames_string': '', 'drugSynonyms_string': 'Fe 202767', 'linkedDiseasesDrug_string': 'Premature Birth (EFO_0003917)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'OXTR (ENSG00000180914)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1244 | Q17 | What gene does the drug Cabozantinib S-Malate target? | The drug Cabozantinib S-Malate targets 2 genes: KDR and MET. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cabozantinib s-malate%" OR LOWER(tradeNames_string) LIKE "%cabozantinib s-malate%" OR LOWER(drugSynonyms_string) LIKE "%cabozantinib s-malate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3579', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_string': 'Cabometyx, Cometriq', 'drugSynonyms_string': 'BMS-907351, Cabozantinib malate, Cabozantinib s-malate, XL-184, XL184', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Papillary Thyroid Carcinoma (EFO_0000641), Thyroid Carcinoma (EFO_0002892), Small Cell Carcinoma (EFO_0008524), Central Nervous System Cancer (EFO_0000326), Angiosarcoma (EFO_0003968), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305), Astrocytoma (EFO_0000272), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Papillary Renal Cell Carcinoma (EFO_0000640), Fallopian Tube Carcinoma (EFO_1000251), Endometrial Carcinoma (EFO_1001512), Clear Cell Renal Carcinoma (EFO_0000349), Renal Cell Carcinoma (EFO_0000681), Thyroid Cancer (MONDO_0002108), Neoplasm (EFO_0000616), Follicular Thyroid Carcinoma (EFO_0000501), Non-Small Cell Lung Carcinoma (EFO_0003060), Glioblastoma Multiforme (EFO_0000519), Adrenal Gland Pheochromocytoma (EFO_0000239)', 'yearOfFirstApproval': 2012, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MET (ENSG00000105976), KDR (ENSG00000128052)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3580', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_string': 'Cabometyx, Cometriq', 'drugSynonyms_string': 'BMS-907351, Cabozantinib malate, Cabozantinib s-malate, XL-184, XL184', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Papillary Thyroid Carcinoma (EFO_0000641), Thyroid Carcinoma (EFO_0002892), Small Cell Carcinoma (EFO_0008524), Central Nervous System Cancer (EFO_0000326), Angiosarcoma (EFO_0003968), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305), Astrocytoma (EFO_0000272), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Papillary Renal Cell Carcinoma (EFO_0000640), Fallopian Tube Carcinoma (EFO_1000251), Endometrial Carcinoma (EFO_1001512), Clear Cell Renal Carcinoma (EFO_0000349), Renal Cell Carcinoma (EFO_0000681), Thyroid Cancer (MONDO_0002108), Neoplasm (EFO_0000616), Follicular Thyroid Carcinoma (EFO_0000501), Non-Small Cell Lung Carcinoma (EFO_0003060), Glioblastoma Multiforme (EFO_0000519), Adrenal Gland Pheochromocytoma (EFO_0000239)', 'yearOfFirstApproval': 2012, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MET (ENSG00000105976), KDR (ENSG00000128052)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1638 | Q17 | What gene does the drug Ticlopidine target? | The drug Ticlopidine targets the gene P2RY12. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ticlopidine%" OR LOWER(tradeNames_string) LIKE "%ticlopidine%" OR LOWER(drugSynonyms_string) LIKE "%ticlopidine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3795', 'drugName': 'Ticlopidine', 'tradeNames_string': '', 'drugSynonyms_string': 'Ticlopidin-puren, Ticlopidine', 'linkedDiseasesDrug_string': 'Recurrent Thrombophlebitis (HP_0004419), Internal Carotid Artery Stenosis (EFO_0002615), Stroke (EFO_0000712), Peripheral Arterial Disease (EFO_0004265), Thrombotic Disease (MONDO_0000831)', 'yearOfFirstApproval': 1991, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'P2RY12 (ENSG00000169313)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1201', 'drugName': 'Ticlopidine Hydrochloride', 'tradeNames_string': 'Ticlid, Ticlopidine hydrochloride, Tiklid', 'drugSynonyms_string': '4-C-32, 53-32C, Ipaton, NSC-759165, Ticlopidine hcl, Ticlopidine hydrochloride', 'linkedDiseasesDrug_string': 'Thrombotic Disease (MONDO_0000831), Stroke (EFO_0000712)', 'yearOfFirstApproval': 1991, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'P2RY12 (ENSG00000169313)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1588 | Q17 | What gene does the drug Angiotensin Ii target? | The drug Angiotensin Ii targets the gene AGTR1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%angiotensin ii%" OR LOWER(tradeNames_string) LIKE "%angiotensin ii%" OR LOWER(drugSynonyms_string) LIKE "%angiotensin ii%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3311', 'drugName': 'Angiotensin Ii', 'tradeNames_string': '', 'drugSynonyms_string': '5-l-isoleucineangiotensin ii, Angiotensin ii, Angiotensin ii (human type), Angiotensin ii human, Asp-arg-val-tyr-ile-his-pro-phe, Delivert, LJPC-501', 'linkedDiseasesDrug_string': 'Orthostatic Hypotension (EFO_0005252), Septic Shock (EFO_0006834), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Renal Insufficiency (HP_0000083)', 'yearOfFirstApproval': 2017, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'AGTR1 (ENSG00000144891)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3664', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_string': 'Giapreza', 'drugSynonyms_string': 'Angiotensin ii acetate, Angiotensin ii acetate human, Angiotensin ii triacetate, Human angiotensin ii acetate salt', 'linkedDiseasesDrug_string': 'Septic Shock (EFO_0006834)', 'yearOfFirstApproval': 2017, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'AGTR1 (ENSG00000144891)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3720', 'drugName': 'Saralasin', 'tradeNames_string': '', 'drugSynonyms_string': '1-sar-8-ala-angiotensin ii, Sar-arg-val-tyr-val-his-pro-ala, Saralasin', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'AGTR1 (ENSG00000144891)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2902', 'drugName': 'Txa127', 'tradeNames_string': '', 'drugSynonyms_string': '5-ile-angiotensin-(1-7), Angiotensin (1-7), Angiotensin 1-7, Angiotensin fragment 1-7, Angiotensin peptide (1-7), Angiotensin-(1-7), Asp-arg-val-tyr-ile-his-pro, Bf-angiotensin 1-7, Human angiotensin ii (1-7), Sh-heptapeptide-13, TXA-127, TXA127, Txa127', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Hiv Infection (EFO_0000764), Neoplasm (EFO_0000616), Peripheral Arterial Disease (EFO_0004265), Heart Failure (EFO_0003144), Hypertension (EFO_0000537), Aging (GO_0007568), Obesity (EFO_0001073), Covid-19 (MONDO_0100096), Respiratory Failure (EFO_0009686), Myelodysplastic Syndrome (EFO_0000198)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'MAS1 (ENSG00000130368)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1316 | Q17 | What gene does the drug Amlodipine Benzoate target? | The drug Amlodipine Benzoate targets 4 genes: CACNA1C, CACNA1D, CACNA1S and CACNA1F. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%amlodipine benzoate%" OR LOWER(tradeNames_string) LIKE "%amlodipine benzoate%" OR LOWER(drugSynonyms_string) LIKE "%amlodipine benzoate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5167', 'drugName': 'Amlodipine Benzoate', 'tradeNames_string': 'Katerzia', 'drugSynonyms_string': 'Amlodipine benzoate', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Coronary Artery Disease (EFO_0001645), Stroke (EFO_0000712), Heart Failure (EFO_0003144), Hypertension (EFO_0000537), Myocardial Infarction (EFO_0000612)', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1779 | Q17 | What gene does the drug Cs-1003 target? | The drug Cs-1003 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene PDCD1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cs-1003%" OR LOWER(tradeNames_string) LIKE "%cs-1003%" OR LOWER(drugSynonyms_string) LIKE "%cs-1003%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6391', 'drugName': 'Cs-1003', 'tradeNames_string': '', 'drugSynonyms_string': 'Antibody cs1003, CS 1003, CS-1003, CS1003, Cs-1003, Cs1003, Nofazinlimab, Recombinant pd-1 mab cs1003', 'linkedDiseasesDrug_string': 'Neoplasm (EFO_0000616), Cancer (MONDO_0004992), Hepatocellular Carcinoma (EFO_0000182), Lymphoma (EFO_0000574)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'PDCD1 (ENSG00000188389)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1647 | Q17 | What gene does the drug Mipomersen target? | The drug Mipomersen targets the gene APOB. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%mipomersen%" OR LOWER(tradeNames_string) LIKE "%mipomersen%" OR LOWER(drugSynonyms_string) LIKE "%mipomersen%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3718', 'drugName': 'Mipomersen Sodium', 'tradeNames_string': 'Kynamro', 'drugSynonyms_string': 'ISIS 301012, ISIS-301012, Mipomersen sodium, Mipomersen sodium salt', 'linkedDiseasesDrug_string': 'Familial Hypercholesterolemia (EFO_0004911), Cardiovascular Disease (EFO_0000319), Hypercholesterolemia (HP_0003124)', 'yearOfFirstApproval': 2013, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'APOB (ENSG00000084674)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5688', 'drugName': 'Mipomersen', 'tradeNames_string': '', 'drugSynonyms_string': 'Mipomersen', 'linkedDiseasesDrug_string': 'Familial Hypercholesterolemia (EFO_0004911), Cardiovascular Disease (EFO_0000319), Hypercholesterolemia (HP_0003124)', 'yearOfFirstApproval': 2013, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'APOB (ENSG00000084674)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1255 | Q17 | What gene does the drug Von Willebrand Factor Human target? | The drug Von Willebrand Factor Human targets the gene VWF. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%von willebrand factor human%" OR LOWER(tradeNames_string) LIKE "%von willebrand factor human%" OR LOWER(drugSynonyms_string) LIKE "%von willebrand factor human%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4930', 'drugName': 'Von Willebrand Factor Human', 'tradeNames_string': '', 'drugSynonyms_string': "Human von willebrand factor, Von willebrand factor, Von willebrand factor (human), Von willebrand factor human, Von willebrand factor, human, Von willebrand's factor", 'linkedDiseasesDrug_string': 'Von Willebrand Disease (Orphanet_903), Hemorrhage (MP_0001914), Von Willebrand Disease (Hereditary Or Acquired) (MONDO_0024574), Postpartum Hemorrhage (EFO_0009579)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'VWF (ENSG00000110799)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1675 | Q17 | What gene does the drug Glpg-1205 target? | The drug Glpg-1205 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene GPR84. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%glpg-1205%" OR LOWER(tradeNames_string) LIKE "%glpg-1205%" OR LOWER(drugSynonyms_string) LIKE "%glpg-1205%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1454', 'drugName': 'Glpg-1205', 'tradeNames_string': '', 'drugSynonyms_string': 'Glpg-1205, Glpg1205', 'linkedDiseasesDrug_string': 'Idiopathic Pulmonary Fibrosis (EFO_0000768), Ulcerative Colitis (EFO_0000729)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'GPR84 (ENSG00000139572)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1801 | Q17 | What gene does the drug Orp-101 target? | The drug Orp-101 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: OPRK1 and OPRM1 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%orp-101%" OR LOWER(tradeNames_string) LIKE "%orp-101%" OR LOWER(drugSynonyms_string) LIKE "%orp-101%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1458', 'drugName': 'Orp-101', 'tradeNames_string': '', 'drugSynonyms_string': 'Buprenorphine dimer, Orp-101', 'linkedDiseasesDrug_string': 'Irritable Bowel Syndrome (EFO_0000555)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1459', 'drugName': 'Orp-101', 'tradeNames_string': '', 'drugSynonyms_string': 'Buprenorphine dimer, Orp-101', 'linkedDiseasesDrug_string': 'Irritable Bowel Syndrome (EFO_0000555)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.759 | Q17 | What gene does the drug Cisatracurium Besylate target? | The drug Cisatracurium Besylate targets 5 genes: CHRNB1, CHRNA1, CHRND, CHRNE and CHRNG. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cisatracurium besylate%" OR LOWER(tradeNames_string) LIKE "%cisatracurium besylate%" OR LOWER(drugSynonyms_string) LIKE "%cisatracurium besylate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3676', 'drugName': 'Cisatracurium Besylate', 'tradeNames_string': 'Cisatracurium besylate, Cisatracurium besylate preservative free, Nimbex, Nimbex preservative free', 'drugSynonyms_string': '51 W89, 51-W-89, 51-W89, 51W-89, 51W89, Cisatracurium (as besilate), Cisatracurium besilate, Cisatracurium besylate', 'linkedDiseasesDrug_string': 'Acute Respiratory Distress Syndrome (EFO_1000637)', 'yearOfFirstApproval': 1995, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'numberLinkedTargets': 5}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.616 | Q17 | What gene does the drug Neramexane Mesylate target? | The drug Neramexane Mesylate is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 9 genes: GRIN2B, GRIN2A, GRIN3A, GRIN2D, CHRNA9, GRIN3B, GRIN1, CHRNA10 and GRIN2C | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%neramexane mesylate%" OR LOWER(tradeNames_string) LIKE "%neramexane mesylate%" OR LOWER(drugSynonyms_string) LIKE "%neramexane mesylate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5793', 'drugName': 'Neramexane Mesylate', 'tradeNames_string': '', 'drugSynonyms_string': 'Neramexane mesilate, Neramexane mesylate', 'linkedDiseasesDrug_string': 'Tinnitus (HP_0000360)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'CHRNA9 (ENSG00000174343), CHRNA10 (ENSG00000129749), GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_5794', 'drugName': 'Neramexane Mesylate', 'tradeNames_string': '', 'drugSynonyms_string': 'Neramexane mesilate, Neramexane mesylate', 'linkedDiseasesDrug_string': 'Tinnitus (HP_0000360)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'CHRNA9 (ENSG00000174343), CHRNA10 (ENSG00000129749), GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785)', 'numberLinkedTargets': 9}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1045 | Q17 | What gene does the drug Propantheline Bromide target? | The drug Propantheline Bromide targets 3 genes: CHRM1, CHRM2 and CHRM3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%propantheline bromide%" OR LOWER(tradeNames_string) LIKE "%propantheline bromide%" OR LOWER(drugSynonyms_string) LIKE "%propantheline bromide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4309', 'drugName': 'Propantheline Bromide', 'tradeNames_string': 'Pro-banthine, Propantheline bromide', 'drugSynonyms_string': 'NSC-757294, Propantheline Bromide, Propantheline bromide', 'linkedDiseasesDrug_string': 'Overactive Bladder (EFO_1000781), Peptic Ulcer Disease (MONDO_0004247)', 'yearOfFirstApproval': 1953, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM1 (ENSG00000168539), CHRM2 (ENSG00000181072)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_4310', 'drugName': 'Propantheline Bromide', 'tradeNames_string': 'Pro-banthine, Propantheline bromide', 'drugSynonyms_string': 'NSC-757294, Propantheline Bromide, Propantheline bromide', 'linkedDiseasesDrug_string': 'Overactive Bladder (EFO_1000781), Peptic Ulcer Disease (MONDO_0004247)', 'yearOfFirstApproval': 1953, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM1 (ENSG00000168539), CHRM2 (ENSG00000181072)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_4311', 'drugName': 'Propantheline Bromide', 'tradeNames_string': 'Pro-banthine, Propantheline bromide', 'drugSynonyms_string': 'NSC-757294, Propantheline Bromide, Propantheline bromide', 'linkedDiseasesDrug_string': 'Overactive Bladder (EFO_1000781), Peptic Ulcer Disease (MONDO_0004247)', 'yearOfFirstApproval': 1953, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM1 (ENSG00000168539), CHRM2 (ENSG00000181072)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.788 | Q17 | What gene does the drug Sitagliptin Phosphate target? | The drug Sitagliptin Phosphate targets the gene DPP4. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%sitagliptin phosphate%" OR LOWER(tradeNames_string) LIKE "%sitagliptin phosphate%" OR LOWER(drugSynonyms_string) LIKE "%sitagliptin phosphate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2411', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_string': 'Janumet Xr, Januvia', 'drugSynonyms_string': 'Glactiv, MK-0431, MK0431, ONO-5435, Sitagliptin monophosphate, Sitagliptin monophosphate anhydrous, Sitagliptin monophosphate monohydrate, Sitagliptin phosphate, Sitagliptin phosphate anhydrous, Sitagliptin phosphate hydrate, Sitagliptin phosphate monohydrate', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Hyperlipidemia (MONDO_0021187), Stroke (EFO_0000712), Myocardial Infarction (EFO_0000612), Renal Insufficiency (HP_0000083), Type 2 Diabetes Mellitus (MONDO_0005148)', 'yearOfFirstApproval': 2006, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DPP4 (ENSG00000197635)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1690 | Q17 | What gene does the drug Naproxen Etemesil target? | The drug Naproxen Etemesil is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: PTGS2 and PTGS1 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%naproxen etemesil%" OR LOWER(tradeNames_string) LIKE "%naproxen etemesil%" OR LOWER(drugSynonyms_string) LIKE "%naproxen etemesil%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5387', 'drugName': 'Naproxen Etemesil', 'tradeNames_string': '', 'drugSynonyms_string': 'LT-NS001, MX-1094, Naproxen etemesil', 'linkedDiseasesDrug_string': 'Osteoarthritis (MONDO_0005178)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.997 | Q17 | What gene does the drug Ilacirnon target? | The drug Ilacirnon is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CCR2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ilacirnon%" OR LOWER(tradeNames_string) LIKE "%ilacirnon%" OR LOWER(drugSynonyms_string) LIKE "%ilacirnon%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1002', 'drugName': 'Ilacirnon', 'tradeNames_string': '', 'drugSynonyms_string': 'CCX-140, CCX140, CCX140-B, Ccx140, Ilacirnon', 'linkedDiseasesDrug_string': 'Type 2 Diabetes Mellitus (MONDO_0005148), Focal Segmental Glomerulosclerosis (EFO_0004236), Diabetic Nephropathy (EFO_0000401)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'CCR2 (ENSG00000121807)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.499 | Q17 | What gene does the drug Ruplizumab target? | The drug Ruplizumab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CD40LG. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ruplizumab%" OR LOWER(tradeNames_string) LIKE "%ruplizumab%" OR LOWER(drugSynonyms_string) LIKE "%ruplizumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_230', 'drugName': 'Ruplizumab', 'tradeNames_string': 'Antova', 'drugSynonyms_string': 'BG-9588, BG9588, HU-5C8, Ruplizumab, hu5c8', 'linkedDiseasesDrug_string': 'Lupus Nephritis (EFO_0005761)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'CD40LG (ENSG00000102245)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1320 | Q17 | What gene does the drug Mexiletine Hydrochloride target? | The drug Mexiletine Hydrochloride targets 10 genes: SCN1A, SCN9A, SCN7A, SCN8A, SCN11A, SCN10A, SCN2A, SCN5A, SCN4A and SCN3A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%mexiletine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%mexiletine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%mexiletine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4048', 'drugName': 'Mexiletine Hydrochloride', 'tradeNames_string': 'Mexiletine hydrochloride, Mexitil, Mexitil p.l.', 'drugSynonyms_string': 'KO 1173 CL, KO-1173, KO-1173 CL, KO-1173-CL, Katen, Mexiletine hcl, Mexiletine hydrochloride, NSC-758639', 'linkedDiseasesDrug_string': 'Ventricular Arrhythmia (HP_0004308), Peripheral Nervous System Disease (EFO_0009387)', 'yearOfFirstApproval': 1985, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.281 | Q17 | What gene does the drug Prt-2607 target? | The drug Prt-2607 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene SYK. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%prt-2607%" OR LOWER(tradeNames_string) LIKE "%prt-2607%" OR LOWER(drugSynonyms_string) LIKE "%prt-2607%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1216', 'drugName': 'Prt-2607', 'tradeNames_string': '', 'drugSynonyms_string': 'BIIB-057, P505-15, PRT-062607, Prt-2607', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'SYK (ENSG00000165025)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1848 | Q17 | What gene does the drug Diethylpropion target? | The drug Diethylpropion targets 2 genes: SLC6A2 and SLC6A3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%diethylpropion%" OR LOWER(tradeNames_string) LIKE "%diethylpropion%" OR LOWER(drugSynonyms_string) LIKE "%diethylpropion%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1630', 'drugName': 'Diethylpropion', 'tradeNames_string': '', 'drugSynonyms_string': '.alpha.-benzoyltriethylamine, Amfepramone, Anfepramone, Anferpramon, C06954, D07444, Diethylcathinone, Diethylpropion, J4.327C', 'linkedDiseasesDrug_string': 'Obesity (EFO_0001073)', 'yearOfFirstApproval': 1959, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1629', 'drugName': 'Diethylpropion', 'tradeNames_string': '', 'drugSynonyms_string': '.alpha.-benzoyltriethylamine, Amfepramone, Anfepramone, Anferpramon, C06954, D07444, Diethylcathinone, Diethylpropion, J4.327C', 'linkedDiseasesDrug_string': 'Obesity (EFO_0001073)', 'yearOfFirstApproval': 1959, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_2344', 'drugName': 'Diethylpropion Hydrochloride', 'tradeNames_string': 'Apisate, Diethylpropion hydrochloride, Tenuate, Tenuate dospan, Tepanil, Tepanil ten-tab', 'drugSynonyms_string': 'Amfepramone hydrochloride, Anorex, D03801, Diethylpropion HCl, Diethylpropion hcl, Diethylpropion hydrochloride, Diethylpropion hydrochloride civ, Dobesin, Moderatan, Prefamone, Regenon', 'linkedDiseasesDrug_string': 'Obesity (EFO_0001073)', 'yearOfFirstApproval': 1959, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_2343', 'drugName': 'Diethylpropion Hydrochloride', 'tradeNames_string': 'Apisate, Diethylpropion hydrochloride, Tenuate, Tenuate dospan, Tepanil, Tepanil ten-tab', 'drugSynonyms_string': 'Amfepramone hydrochloride, Anorex, D03801, Diethylpropion HCl, Diethylpropion hcl, Diethylpropion hydrochloride, Diethylpropion hydrochloride civ, Dobesin, Moderatan, Prefamone, Regenon', 'linkedDiseasesDrug_string': 'Obesity (EFO_0001073)', 'yearOfFirstApproval': 1959, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.363 | Q17 | What gene does the drug Ergocalciferol target? | The drug Ergocalciferol targets the gene VDR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ergocalciferol%" OR LOWER(tradeNames_string) LIKE "%ergocalciferol%" OR LOWER(drugSynonyms_string) LIKE "%ergocalciferol%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_356', 'drugName': 'Ergocalciferol', 'tradeNames_string': 'Calciferol, Calciferol in arach oil, Caltrate, D-forte, Deltalin, Drisdol, Eciferol d2, Ergo-d2, Ergocalciferol, Ergoral d2, Lanes, Oleovitamin D, Osto-d2, Sterogyl, Sterogyl 15h, Sterogyl-15, Uvesterol d, Vitamin D 2, Vitamin d', 'drugSynonyms_string': 'Calciferol, Ergocalciferol, Ergocalciferolum, Ergorone, NSC-62792, Oleovitamin d, synthetic, Ostelin, Viosterol, Viosterol in oil, Vitamin d (ergocalciferol), Vitamin d2', 'linkedDiseasesDrug_string': "Postmenopausal Osteoporosis (EFO_0003854), Migraine Disorder (MONDO_0005277), Disseminated Intravascular Coagulation (HP_0005521), Pregnancy (EFO_0002950), Malignant Colon Neoplasm (MONDO_0021063), Spinal Cord Injury (EFO_1001919), Osteoporosis (EFO_0003882), Polycystic Ovary Syndrome (EFO_0000660), Vitamin D Deficiency (EFO_0003762), Neuropathic Pain (EFO_0005762), Non-Alcoholic Fatty Liver Disease (EFO_0003095), Bone Fracture (EFO_0003931), Optic Neuritis (EFO_0007405), Abnormality Of Connective Tissue (HP_0003549), Alopecia Areata (EFO_0004192), Hypoparathyroidism (EFO_0009451), Menopause (EFO_0003922), Primary Hyperparathyroidism (EFO_0008519), Sickle Cell Anemia (MONDO_0011382), Cervical Cancer (MONDO_0002974), Lung Cancer (MONDO_0008903), Diabetic Neuropathy (EFO_1000783), Leukemia (EFO_0000565), Giant Cell Tumor (MONDO_0002171), Burn (EFO_0009516), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Multiple Sclerosis (MONDO_0005301), Pain (EFO_0003843), Obesity (EFO_0001073), Pulmonary Tuberculosis (EFO_1000049), Colorectal Carcinoma (EFO_1001951), Hyperprolactinemia (EFO_0007319), Myocardial Ischemia (EFO_1001375), Sudden Cardiac Arrest (EFO_0004278), Restless Legs Syndrome (EFO_0004270), Asthma (MONDO_0004979), Insulin Resistance (EFO_0002614), Sarcopenia (EFO_1000653), Chronic Hepatitis C Virus Infection (EFO_0004220), Chronic Kidney Disease (EFO_0003884), Hiv Infection (EFO_0000764), Colonic Neoplasm (EFO_0004288), Hypophosphatemic Rickets (MONDO_0024300), Hypocalcemia (HP_0002901), Diabetes Mellitus (EFO_0000400), Alzheimer Disease (MONDO_0004975), Cutaneous Lupus Erythematosus (EFO_0003834), Psoriasis Vulgaris (EFO_1001494), Breast Neoplasm (EFO_0003869), Osteopenia (HP_0000938), Breast Cancer (MONDO_0007254), Osteoarthritis, Knee (EFO_0004616), Lymphoma (EFO_0000574), Premature Birth (EFO_0003917), Gestational Diabetes (EFO_0004593), Cutaneous Melanoma (EFO_0000389), Osteogenesis Imperfecta (MONDO_0019019), Heart Failure (EFO_0003144), Tuberculosis (MONDO_0018076), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148), X-Linked Hypophosphatemia (Orphanet_89936), Hypophosphatemia (HP_0002148), Latent Autoimmune Diabetes In Adults (EFO_0009706), Hip Fracture (EFO_0003964), Covid-19 (MONDO_0100096), Femoral Neck Fracture (EFO_1001792), Bone Giant Cell Tumor (EFO_0007176), Endometrial Cancer (MONDO_0011962), Ulcerative Colitis (EFO_0000729), Prostate Adenocarcinoma (EFO_0000673), Inflammatory Bowel Disease (EFO_0003767), Hepatitis C Virus Infection (EFO_0003047), Prostate Cancer (MONDO_0008315), Crohn'S Disease (EFO_0000384), Mood Disorder (EFO_0004247), Osteitis Deformans (EFO_0004261), Disorder Of Lipid Metabolism (Orphanet_309005), Malnutrition (EFO_0008572), Blood Coagulation Disease (EFO_0009314)", 'yearOfFirstApproval': 1941, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'VDR (ENSG00000111424)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4241', 'drugName': 'Doxercalciferol', 'tradeNames_string': 'Doxercalciferol, Hectorol', 'drugSynonyms_string': '1-.alpha.-hydroxyergocalciferol, 1-alpha-hydroxyergocalciferol, 1-hydroxyergocalciferol, 1.alpha.-hydroxyergocalciferol, 1.alpha.-hydroxyvitamin d2, Doxercalciferol, GZ427397, TSA-840', 'linkedDiseasesDrug_string': 'Psoriasis (EFO_0000676), Chronic Kidney Disease (EFO_0003884), Prostate Cancer (MONDO_0008315), Neoplasm (EFO_0000616), Secondary Hyperparathyroidism (EFO_1001173), Parathyroid Disease (EFO_0005754)', 'yearOfFirstApproval': 1999, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'VDR (ENSG00000111424)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1179 | Q17 | What gene does the drug Asenapine Maleate target? | The drug Asenapine Maleate targets 2 genes: HTR2A and DRD2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%asenapine maleate%" OR LOWER(tradeNames_string) LIKE "%asenapine maleate%" OR LOWER(drugSynonyms_string) LIKE "%asenapine maleate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4103', 'drugName': 'Asenapine Maleate', 'tradeNames_string': 'Saphris', 'drugSynonyms_string': 'Asenapine (as maleate), Asenapine maleate, ORG 5222, ORG-5222', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Bipolar I Disorder (EFO_0009963), Schizoaffective Disorder (EFO_0005411), Bipolar Disorder (MONDO_0004985), Stuttering (HP_0025268), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 2009, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), DRD2 (ENSG00000149295)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4104', 'drugName': 'Asenapine Maleate', 'tradeNames_string': 'Saphris', 'drugSynonyms_string': 'Asenapine (as maleate), Asenapine maleate, ORG 5222, ORG-5222', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Bipolar I Disorder (EFO_0009963), Schizoaffective Disorder (EFO_0005411), Bipolar Disorder (MONDO_0004985), Stuttering (HP_0025268), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 2009, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), DRD2 (ENSG00000149295)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.239 | Q17 | What gene does the drug Amivantamab target? | The drug Amivantamab targets 2 genes: MET and EGFR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%amivantamab%" OR LOWER(tradeNames_string) LIKE "%amivantamab%" OR LOWER(drugSynonyms_string) LIKE "%amivantamab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_61', 'drugName': 'Amivantamab', 'tradeNames_string': 'Rybrevant', 'drugSynonyms_string': 'Amivantamab, Amivantamab vmjw, Amivantamab-vmjw, CNTO-4424, CNTO4424, JNJ 61186372, JNJ-611, JNJ-61186372, JNJ-6372, Jnj 61186372, Jnj-61186372', 'linkedDiseasesDrug_string': 'Salivary Gland Cancer (MONDO_0004669), Non-Small Cell Lung Carcinoma (EFO_0003060), Gastric Cancer (MONDO_0001056), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MET (ENSG00000105976), EGFR (ENSG00000146648)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_62', 'drugName': 'Amivantamab', 'tradeNames_string': 'Rybrevant', 'drugSynonyms_string': 'Amivantamab, Amivantamab vmjw, Amivantamab-vmjw, CNTO-4424, CNTO4424, JNJ 61186372, JNJ-611, JNJ-61186372, JNJ-6372, Jnj 61186372, Jnj-61186372', 'linkedDiseasesDrug_string': 'Salivary Gland Cancer (MONDO_0004669), Non-Small Cell Lung Carcinoma (EFO_0003060), Gastric Cancer (MONDO_0001056), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MET (ENSG00000105976), EGFR (ENSG00000146648)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.557 | Q17 | What gene does the drug Ziralimumab target? | The drug Ziralimumab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene BSG. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ziralimumab%" OR LOWER(tradeNames_string) LIKE "%ziralimumab%" OR LOWER(drugSynonyms_string) LIKE "%ziralimumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3581', 'drugName': 'Ziralimumab', 'tradeNames_string': '', 'drugSynonyms_string': 'ABX-RB2, Ziralimumab', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'BSG (ENSG00000172270)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1870 | Q17 | What gene does the drug Pregabalin target? | The drug Pregabalin targets 26 genes: CACNA1C, CACNA1H, CACNG2, CACNG7, CACNA2D1, CACNG6, CACNA1B, CACNG5, CACNG3, CACNG1, CACNB3, CACNB4, CACNA1S, CACNA2D3, CACNA1A, CACNA2D4, CACNA1D, CACNB2, CACNA1G, CACNA1I, CACNG8, CACNB1, CACNG4, CACNA1E, CACNA2D2 and CACNA1F. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pregabalin%" OR LOWER(tradeNames_string) LIKE "%pregabalin%" OR LOWER(drugSynonyms_string) LIKE "%pregabalin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2991', 'drugName': 'Pregabalin', 'tradeNames_string': 'Alzain, Axalid, Lecaent, Lyrica, Lyrica cr, Pregabalin, Rewisca', 'drugSynonyms_string': 'CI-1008, NSC-759256, PD-144723, Pregabalin, Pregabalin mylan, Pregabalin sandoz, Pregabalin sandoz gmbh, Pregabalin zentiva, Vronogabic, YNP-1807', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Complex Regional Pain Syndrome (EFO_1001998), Nausea (HP_0002018), Peripheral Neuropathy (EFO_0003100), Overactive Bladder (EFO_1000781), Migraine Disorder (MONDO_0005277), Cough (HP_0012735), Pain (EFO_0003843), Focal-Onset Seizure (HP_0007359), Irritable Bowel Syndrome (EFO_0000555), Cannabis Dependence (EFO_0007191), Dry Eye Syndrome (EFO_1000906), Mononeuropathy (EFO_0009558), Refractive Error (MONDO_0004892), Muscle Cramp (EFO_0009846), Pregnancy (EFO_0002950), Neuropathy (EFO_0004149), Spinal Cord Injury (EFO_1001919), Breast Cancer (MONDO_0007254), Nicotine Dependence (EFO_0003768), Intervertebral Disc Degeneration (HP_0008419), Dementia (HP_0000726), Neuropathic Pain (EFO_0005762), Anxiety (EFO_0005230), Fibromyalgia (EFO_0005687), Partial Epilepsy (EFO_0004263), Epilepsy (EFO_0000474), Chronic Pancreatitis (EFO_0000342), Seizure (HP_0001250), Herpes Zoster (EFO_0006510), Neurotic Disorder (EFO_0004257), Bone Fracture (EFO_0003931), Complex Partial Epilepsy (EFO_1000877), Pruritus (HP_0000989), Restless Legs Syndrome (EFO_0004270), Oropharynx Cancer (EFO_1001931), Generalized Anxiety Disorder (EFO_1001892), Depressive Disorder (MONDO_0002050), Insomnia (EFO_0004698), Alcohol Dependence (MONDO_0007079), Bilateral Tonic-Clonic Seizure (HP_0002069), Opioid Dependence (EFO_0005611), Osteoarthritis (MONDO_0005178), Diabetic Neuropathy (EFO_1000783), Essential Tremor (EFO_0003108), Squamous Cell Carcinoma (EFO_0000707), Postherpetic Neuralgia (MONDO_0041052), Chronic Pain (HP_0012532), Radiculopathy (MONDO_0002959), Prostatitis (EFO_0003830), Neuralgia (EFO_0009430), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 2004, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1H (ENSG00000196557), CACNA2D1 (ENSG00000153956), CACNA1C (ENSG00000151067), CACNA2D3 (ENSG00000157445), CACNA1S (ENSG00000081248), CACNA2D2 (ENSG00000007402), CACNA1D (ENSG00000157388), CACNA1A (ENSG00000141837), CACNA1B (ENSG00000148408), CACNA1G (ENSG00000006283), CACNA2D4 (ENSG00000151062), CACNA1I (ENSG00000100346), CACNA1F (ENSG00000102001), CACNA1E (ENSG00000198216), CACNB4 (ENSG00000182389), CACNB2 (ENSG00000165995), CACNB1 (ENSG00000067191), CACNB3 (ENSG00000167535), CACNG7 (ENSG00000105605), CACNG5 (ENSG00000075429), CACNG2 (ENSG00000166862), CACNG4 (ENSG00000075461), CACNG8 (ENSG00000142408), CACNG3 (ENSG00000006116), CACNG6 (ENSG00000130433), CACNG1 (ENSG00000108878)', 'numberLinkedTargets': 26}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1915 | Q17 | What gene does the drug At-1501 target? | The drug At-1501 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CD40LG. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%at-1501%" OR LOWER(tradeNames_string) LIKE "%at-1501%" OR LOWER(drugSynonyms_string) LIKE "%at-1501%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2654', 'drugName': 'At-1501', 'tradeNames_string': '', 'drugSynonyms_string': 'AT-1501, At-1501', 'linkedDiseasesDrug_string': 'Type 1 Diabetes Mellitus (MONDO_0005147), Iga Glomerulonephritis (EFO_0004194), Amyotrophic Lateral Sclerosis (MONDO_0004976)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'CD40LG (ENSG00000102245)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.211 | Q17 | What gene does the drug Gancotamab target? | The drug Gancotamab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: ERBB2 and TOP2A | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%gancotamab%" OR LOWER(tradeNames_string) LIKE "%gancotamab%" OR LOWER(drugSynonyms_string) LIKE "%gancotamab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2111', 'drugName': 'Gancotamab', 'tradeNames_string': '', 'drugSynonyms_string': 'Gancotamab, MM-302, Mm-302', 'linkedDiseasesDrug_string': 'Breast Cancer (MONDO_0007254)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'TOP2A (ENSG00000131747), ERBB2 (ENSG00000141736)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_2112', 'drugName': 'Gancotamab', 'tradeNames_string': '', 'drugSynonyms_string': 'Gancotamab, MM-302, Mm-302', 'linkedDiseasesDrug_string': 'Breast Cancer (MONDO_0007254)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'TOP2A (ENSG00000131747), ERBB2 (ENSG00000141736)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1922 | Q17 | What gene does the drug Prenylamine target? | The drug Prenylamine targets 2 genes: SCN5A and CALM1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%prenylamine%" OR LOWER(tradeNames_string) LIKE "%prenylamine%" OR LOWER(drugSynonyms_string) LIKE "%prenylamine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5448', 'drugName': 'Prenylamine', 'tradeNames_string': '', 'drugSynonyms_string': 'B-436, Prenylamine, Prenylamine lactate', 'linkedDiseasesDrug_string': 'Cardiovascular Disease (EFO_0000319)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN5A (ENSG00000183873), CALM1 (ENSG00000198668)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5449', 'drugName': 'Prenylamine', 'tradeNames_string': '', 'drugSynonyms_string': 'B-436, Prenylamine, Prenylamine lactate', 'linkedDiseasesDrug_string': 'Cardiovascular Disease (EFO_0000319)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN5A (ENSG00000183873), CALM1 (ENSG00000198668)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1561 | Q17 | What gene does the drug Osimertinib Mesylate target? | The drug Osimertinib Mesylate targets the gene EGFR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%osimertinib mesylate%" OR LOWER(tradeNames_string) LIKE "%osimertinib mesylate%" OR LOWER(drugSynonyms_string) LIKE "%osimertinib mesylate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_649', 'drugName': 'Osimertinib Mesylate', 'tradeNames_string': 'Tagrisso', 'drugSynonyms_string': 'AZD-9291 MESYLATE, AZD9291 mesylate, Mereletinib mesilate, Mereletinib mesylate, Osimertinib mesilate, Osimertinib mesylate', 'linkedDiseasesDrug_string': 'Non-Small Cell Lung Carcinoma (EFO_0003060), Lung Cancer (MONDO_0008903)', 'yearOfFirstApproval': 2015, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'EGFR (ENSG00000146648)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.60 | Q17 | What gene does the drug Oxymetazoline Hydrochloride target? | The drug Oxymetazoline Hydrochloride targets 6 genes: ADRA2A, ADRA2C, ADRA1A, ADRA1D, ADRA2B and ADRA1B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%oxymetazoline hydrochloride%" OR LOWER(tradeNames_string) LIKE "%oxymetazoline hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%oxymetazoline hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_543', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_string': 'Afrazine, Ocuclear, Rhofade, Upneeq, Visine, Visine l.r.', 'drugSynonyms_string': 'Agn-199201, NSC-757254, Oximetazoline hydrochloride, Oxymetazoline hcl, Oxymetazoline hydrochloride, SCH 9384, SCH-9384', 'linkedDiseasesDrug_string': 'Allergic Conjunctivitis (EFO_0007141), Sinusitis (EFO_0007486), Rosacea (EFO_1000760), Common Cold (EFO_0007214), Presbyopia (MONDO_0001330), Seasonal Allergic Rhinitis (EFO_0003956), Erythema (HP_0010783), Allergic Rhinitis (EFO_0005854), Nasal Congestion (HP_0001742), Ptosis (MONDO_0000728)', 'yearOfFirstApproval': 1986, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286)', 'numberLinkedTargets': 6}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1835 | Q17 | What gene does the drug Methylphenidate Hydrochloride target? | The drug Methylphenidate Hydrochloride targets 2 genes: SLC6A2 and SLC6A3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%methylphenidate hydrochloride%" OR LOWER(tradeNames_string) LIKE "%methylphenidate hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%methylphenidate hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_846', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_string': 'Adhansia xr, Aptensio xr, Concerta, Delmosart, Equasym, Equasym xl, Jornay pm, Matoride xl, Medikinet, Medikinet xl, Metadate cd, Metadate er, Methylin, Methylin er, Methylphenidate hydrochloride, Quillichew er, Quillivant xr, Relexxii, Ritalin, Ritalin la, Ritalin sr, Ritalin-sr, Tranquilyn, Xenidate xl', 'drugSynonyms_string': 'Aptensio, Aptensio xr, Foquest, Metadate, Methylphenidate HCl, Methylphenidate hcl, Methylphenidate hydrochloride, Methylphenidate hydrochloride cii, NSC-169868, Oros mph, Quillichew, Quillivant, SPD-544, SPD544', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Sleep Disorder (EFO_0008568), Conduct Disorder (EFO_0004216), Nicotine Dependence (EFO_0003768), Chronic Progressive Multiple Sclerosis (EFO_0003840), Attention Deficit Hyperactivity Disorder (EFO_0003888), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Fatigue (HP_0012378), Depressive Disorder (MONDO_0002050), Schizophrenia (MONDO_0005090), Childhood Apraxia Of Speech (MONDO_0011184)', 'yearOfFirstApproval': 1955, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_845', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_string': 'Adhansia xr, Aptensio xr, Concerta, Delmosart, Equasym, Equasym xl, Jornay pm, Matoride xl, Medikinet, Medikinet xl, Metadate cd, Metadate er, Methylin, Methylin er, Methylphenidate hydrochloride, Quillichew er, Quillivant xr, Relexxii, Ritalin, Ritalin la, Ritalin sr, Ritalin-sr, Tranquilyn, Xenidate xl', 'drugSynonyms_string': 'Aptensio, Aptensio xr, Foquest, Metadate, Methylphenidate HCl, Methylphenidate hcl, Methylphenidate hydrochloride, Methylphenidate hydrochloride cii, NSC-169868, Oros mph, Quillichew, Quillivant, SPD-544, SPD544', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Sleep Disorder (EFO_0008568), Conduct Disorder (EFO_0004216), Nicotine Dependence (EFO_0003768), Chronic Progressive Multiple Sclerosis (EFO_0003840), Attention Deficit Hyperactivity Disorder (EFO_0003888), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Fatigue (HP_0012378), Depressive Disorder (MONDO_0002050), Schizophrenia (MONDO_0005090), Childhood Apraxia Of Speech (MONDO_0011184)', 'yearOfFirstApproval': 1955, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5957', 'drugName': 'Dexmethylphenidate Hydrochloride', 'tradeNames_string': 'Dexmethylphenidate hydrochloride, Focalin, Focalin xr', 'drugSynonyms_string': 'Dex-methylphenidate hydrochloride, Dexmethylphenidate hcl, Dexmethylphenidate hydrochloride, Methylphenidate d-threo-form hydrochloride', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5956', 'drugName': 'Dexmethylphenidate Hydrochloride', 'tradeNames_string': 'Dexmethylphenidate hydrochloride, Focalin, Focalin xr', 'drugSynonyms_string': 'Dex-methylphenidate hydrochloride, Dexmethylphenidate hcl, Dexmethylphenidate hydrochloride, Methylphenidate d-threo-form hydrochloride', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1906 | Q17 | What gene does the drug Otlertuzumab target? | The drug Otlertuzumab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CD37. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%otlertuzumab%" OR LOWER(tradeNames_string) LIKE "%otlertuzumab%" OR LOWER(drugSynonyms_string) LIKE "%otlertuzumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1405', 'drugName': 'Otlertuzumab', 'tradeNames_string': '', 'drugSynonyms_string': 'Otlertuzumab, TRU-016', 'linkedDiseasesDrug_string': 'Chronic Lymphocytic Leukemia (EFO_0000095)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'CD37 (ENSG00000104894)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1578 | Q17 | What gene does the drug Tanzisertib target? | The drug Tanzisertib is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 3 genes: MAPK10, MAPK9 and MAPK8 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tanzisertib%" OR LOWER(tradeNames_string) LIKE "%tanzisertib%" OR LOWER(drugSynonyms_string) LIKE "%tanzisertib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1117', 'drugName': 'Tanzisertib', 'tradeNames_string': '', 'drugSynonyms_string': 'CC-930, JNK 930, JNK-930, Tanzisertib', 'linkedDiseasesDrug_string': 'Idiopathic Pulmonary Fibrosis (EFO_0000768)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'MAPK9 (ENSG00000050748), MAPK8 (ENSG00000107643), MAPK10 (ENSG00000109339)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_1118', 'drugName': 'Tanzisertib', 'tradeNames_string': '', 'drugSynonyms_string': 'CC-930, JNK 930, JNK-930, Tanzisertib', 'linkedDiseasesDrug_string': 'Idiopathic Pulmonary Fibrosis (EFO_0000768)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'MAPK9 (ENSG00000050748), MAPK8 (ENSG00000107643), MAPK10 (ENSG00000109339)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_1119', 'drugName': 'Tanzisertib', 'tradeNames_string': '', 'drugSynonyms_string': 'CC-930, JNK 930, JNK-930, Tanzisertib', 'linkedDiseasesDrug_string': 'Idiopathic Pulmonary Fibrosis (EFO_0000768)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'MAPK9 (ENSG00000050748), MAPK8 (ENSG00000107643), MAPK10 (ENSG00000109339)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.368 | Q17 | What gene does the drug Ibritumomab Tiuxetan target? | The drug Ibritumomab Tiuxetan targets the gene MS4A1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ibritumomab tiuxetan%" OR LOWER(tradeNames_string) LIKE "%ibritumomab tiuxetan%" OR LOWER(drugSynonyms_string) LIKE "%ibritumomab tiuxetan%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3680', 'drugName': 'Ibritumomab Tiuxetan', 'tradeNames_string': 'Zevalin, Zevalin Kit-Indium-111', 'drugSynonyms_string': 'IDEC-129, IDEC-IN2B8, IDEC-Y2B8, IDEC-Y2B8 IDEC-129, Ibritumomab tiuxetan', 'linkedDiseasesDrug_string': 'Multiple Myeloma (EFO_0001378), Follicular Lymphoma (MONDO_0018906), Chronic Lymphocytic Leukemia (EFO_0000095), Non-Hodgkins Lymphoma (EFO_0005952), Leukemia (EFO_0000565), Neoplasm Of Mature B-Cells (EFO_0000096), Lymphoma, Aids-Related (EFO_1001365), Mantle Cell Lymphoma (EFO_1001469), Graft Versus Host Disease (MONDO_0013730), Lymphoblastic Lymphoma (MONDO_0000873), Lymphoma (EFO_0000574), Waldenstrom Macroglobulinemia (EFO_0009441), Burkitts Lymphoma (EFO_0000309), Diffuse Large B-Cell Lymphoma (EFO_0000403), Malt Lymphoma (EFO_0000191), Hodgkins Lymphoma (EFO_0000183)', 'yearOfFirstApproval': 2002, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MS4A1 (ENSG00000156738)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1480', 'drugName': 'Yttrium Y 90 Ibritumomab Tiuxetan', 'tradeNames_string': '', 'drugSynonyms_string': '(90)y-ibritumomab tiuxetan, 90y ibritumomab tiuxetan, 90y-ibritumomab, BAY-86-5128, Ibritumomab tiuxetan, Ibritumomab tiuxetan y-90, Ibritumomab tiuxetan yttrium y-90, Yttrium y 90 ibritumomab tiuxetan, Yttrium y-90 ibritumomab tiuxetan', 'linkedDiseasesDrug_string': 'Multiple Myeloma (EFO_0001378), Non-Hodgkins Lymphoma (EFO_0005952), Mantle Cell Lymphoma (EFO_1001469), Chronic Lymphocytic Leukemia (EFO_0000095), Leukemia (EFO_0000565), Neoplasm Of Mature B-Cells (EFO_0000096), Lymphoma, Aids-Related (EFO_1001365), Follicular Lymphoma (MONDO_0018906), Graft Versus Host Disease (MONDO_0013730), Lymphoblastic Lymphoma (MONDO_0000873), Lymphoma (EFO_0000574), Anaplastic Large Cell Lymphoma (EFO_0003032), Waldenstrom Macroglobulinemia (EFO_0009441), Burkitts Lymphoma (EFO_0000309), Diffuse Large B-Cell Lymphoma (EFO_0000403), Malt Lymphoma (EFO_0000191), Hodgkins Lymphoma (EFO_0000183)', 'yearOfFirstApproval': 2002, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MS4A1 (ENSG00000156738)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.511 | Q17 | What gene does the drug Cilazapril target? | The drug Cilazapril targets the gene ACE. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cilazapril%" OR LOWER(tradeNames_string) LIKE "%cilazapril%" OR LOWER(drugSynonyms_string) LIKE "%cilazapril%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3862', 'drugName': 'Cilazapril', 'tradeNames_string': 'Inhibace, Vascace', 'drugSynonyms_string': 'Anhydrous cilazapril, Cilazapril, Cilazapril anhydrous, Cilazapril hydrate, Cilazapril monohydrate, Cilazaprilum, Initiss, Justor, RO 31-2848/006, RO-312848006', 'linkedDiseasesDrug_string': 'Cardiovascular Disease (EFO_0000319)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ACE (ENSG00000159640)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.815 | Q17 | What gene does the drug Ataciguat target? | The drug Ataciguat is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 4 genes: GUCY1A1, GUCY1B2, GUCY1A2 and GUCY1B1 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ataciguat%" OR LOWER(tradeNames_string) LIKE "%ataciguat%" OR LOWER(drugSynonyms_string) LIKE "%ataciguat%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3371', 'drugName': 'Ataciguat', 'tradeNames_string': '', 'drugSynonyms_string': 'Ataciguat', 'linkedDiseasesDrug_string': 'Aortic Stenosis (EFO_0000266), Pain (EFO_0003843), Intermittent Vascular Claudication (EFO_0003876)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'GUCY1B1 (ENSG00000061918), GUCY1B2 (ENSG00000123201), GUCY1A2 (ENSG00000152402), GUCY1A1 (ENSG00000164116)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1122 | Q17 | What gene does the drug Desflurane target? | The drug Desflurane targets 23 genes: GLRB, GABRG2, GABRA4, KCNK9, GABRB3, GABRA2, KCNK3, KCNK10, GABRA1, GLRA1, GABRE, GABRP, GABRG3, GABRB1, GABRA6, KCNK2, KCNK18, GABRA5, GABRQ, GABRD, GABRA3, GABRB2 and GABRG1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%desflurane%" OR LOWER(tradeNames_string) LIKE "%desflurane%" OR LOWER(drugSynonyms_string) LIKE "%desflurane%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3266', 'drugName': 'Desflurane', 'tradeNames_string': 'Suprane', 'drugSynonyms_string': 'Desflurane, I-653', 'linkedDiseasesDrug_string': 'Post-Operative Sign Or Symptom (EFO_0005323), Kidney Failure (EFO_1002048)', 'yearOfFirstApproval': 1992, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK10 (ENSG00000100433), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), KCNK2 (ENSG00000082482), KCNK3 (ENSG00000171303), KCNK18 (ENSG00000186795)', 'numberLinkedTargets': 23}, {'UUID': 'DrugGeneTargets_v2_3264', 'drugName': 'Desflurane', 'tradeNames_string': 'Suprane', 'drugSynonyms_string': 'Desflurane, I-653', 'linkedDiseasesDrug_string': 'Post-Operative Sign Or Symptom (EFO_0005323), Kidney Failure (EFO_1002048)', 'yearOfFirstApproval': 1992, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK10 (ENSG00000100433), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), KCNK2 (ENSG00000082482), KCNK3 (ENSG00000171303), KCNK18 (ENSG00000186795)', 'numberLinkedTargets': 23}, {'UUID': 'DrugGeneTargets_v2_3262', 'drugName': 'Desflurane', 'tradeNames_string': 'Suprane', 'drugSynonyms_string': 'Desflurane, I-653', 'linkedDiseasesDrug_string': 'Post-Operative Sign Or Symptom (EFO_0005323), Kidney Failure (EFO_1002048)', 'yearOfFirstApproval': 1992, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK10 (ENSG00000100433), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), KCNK2 (ENSG00000082482), KCNK3 (ENSG00000171303), KCNK18 (ENSG00000186795)', 'numberLinkedTargets': 23}, {'UUID': 'DrugGeneTargets_v2_3261', 'drugName': 'Desflurane', 'tradeNames_string': 'Suprane', 'drugSynonyms_string': 'Desflurane, I-653', 'linkedDiseasesDrug_string': 'Post-Operative Sign Or Symptom (EFO_0005323), Kidney Failure (EFO_1002048)', 'yearOfFirstApproval': 1992, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK10 (ENSG00000100433), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), KCNK2 (ENSG00000082482), KCNK3 (ENSG00000171303), KCNK18 (ENSG00000186795)', 'numberLinkedTargets': 23}, {'UUID': 'DrugGeneTargets_v2_3267', 'drugName': 'Desflurane', 'tradeNames_string': 'Suprane', 'drugSynonyms_string': 'Desflurane, I-653', 'linkedDiseasesDrug_string': 'Post-Operative Sign Or Symptom (EFO_0005323), Kidney Failure (EFO_1002048)', 'yearOfFirstApproval': 1992, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK10 (ENSG00000100433), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), KCNK2 (ENSG00000082482), KCNK3 (ENSG00000171303), KCNK18 (ENSG00000186795)', 'numberLinkedTargets': 23}, {'UUID': 'DrugGeneTargets_v2_3265', 'drugName': 'Desflurane', 'tradeNames_string': 'Suprane', 'drugSynonyms_string': 'Desflurane, I-653', 'linkedDiseasesDrug_string': 'Post-Operative Sign Or Symptom (EFO_0005323), Kidney Failure (EFO_1002048)', 'yearOfFirstApproval': 1992, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK10 (ENSG00000100433), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), KCNK2 (ENSG00000082482), KCNK3 (ENSG00000171303), KCNK18 (ENSG00000186795)', 'numberLinkedTargets': 23}, {'UUID': 'DrugGeneTargets_v2_3263', 'drugName': 'Desflurane', 'tradeNames_string': 'Suprane', 'drugSynonyms_string': 'Desflurane, I-653', 'linkedDiseasesDrug_string': 'Post-Operative Sign Or Symptom (EFO_0005323), Kidney Failure (EFO_1002048)', 'yearOfFirstApproval': 1992, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK10 (ENSG00000100433), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), KCNK2 (ENSG00000082482), KCNK3 (ENSG00000171303), KCNK18 (ENSG00000186795)', 'numberLinkedTargets': 23}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1731 | Q17 | What gene does the drug Lumiliximab target? | The drug Lumiliximab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene FCER2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lumiliximab%" OR LOWER(tradeNames_string) LIKE "%lumiliximab%" OR LOWER(drugSynonyms_string) LIKE "%lumiliximab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2670', 'drugName': 'Lumiliximab', 'tradeNames_string': '', 'drugSynonyms_string': 'Gomiliximab, IDEC-152, Lumiliximab, P5E8 SI-3401 GOMILIXIMAB, Primatized anti-cd23, ST-152', 'linkedDiseasesDrug_string': 'Leukemia (EFO_0000565), Chronic Lymphocytic Leukemia (EFO_0000095), Lymphoma (EFO_0000574)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'FCER2 (ENSG00000104921)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1216 | Q17 | What gene does the drug Gallium Nitrate target? | The drug Gallium Nitrate targets 3 genes: RRM1, RRM2B and RRM2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%gallium nitrate%" OR LOWER(tradeNames_string) LIKE "%gallium nitrate%" OR LOWER(drugSynonyms_string) LIKE "%gallium nitrate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3632', 'drugName': 'Gallium Nitrate', 'tradeNames_string': 'Ganite', 'drugSynonyms_string': 'Gallium nitrate, Gallium nitrate (anhydrous), Gallium nitrate anhydrous, Gallium nitrate nonahydrate, NSC-15200, Nitric acid, gallium salt', 'linkedDiseasesDrug_string': 'Central Nervous System Neoplasm (EFO_1000158), Neuroblastoma (EFO_0000621), Non-Hodgkins Lymphoma (EFO_0005952), Mycobacterium Infection (EFO_0009429), Sarcoma (EFO_0000691), Lymphoma (EFO_0000574), Cystic Fibrosis (MONDO_0009061)', 'yearOfFirstApproval': 1991, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'RRM1 (ENSG00000167325), RRM2B (ENSG00000048392), RRM2 (ENSG00000171848)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1212 | Q17 | What gene does the drug Vonicog Alfa target? | The drug Vonicog Alfa is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene VWF. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%vonicog alfa%" OR LOWER(tradeNames_string) LIKE "%vonicog alfa%" OR LOWER(drugSynonyms_string) LIKE "%vonicog alfa%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3183', 'drugName': 'Vonicog Alfa', 'tradeNames_string': '', 'drugSynonyms_string': 'BAX 111, BAX-111, Von willebrand factor (recombinant), Vonicog alfa, Vonvendi', 'linkedDiseasesDrug_string': 'Von Willebrand Disease (Orphanet_903)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'VWF (ENSG00000110799)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.971 | Q17 | What gene does the drug Proparacaine Hydrochloride target? | The drug Proparacaine Hydrochloride targets 10 genes: SCN1A, SCN9A, SCN7A, SCN8A, SCN11A, SCN10A, SCN2A, SCN5A, SCN4A and SCN3A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%proparacaine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%proparacaine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%proparacaine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2948', 'drugName': 'Proparacaine Hydrochloride', 'tradeNames_string': 'Alcaine, Kainair, Ophthaine, Ophthetic, Paracaine, Proparacaine hydrochloride', 'drugSynonyms_string': 'Ak-taine, NSC-759896, Proparacaine hcl, Proparacaine hydrochloride, Proxymetacaine, Proxymetacaine hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1953, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.805 | Q17 | What gene does the drug Giloralimab target? | The drug Giloralimab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CD40. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%giloralimab%" OR LOWER(tradeNames_string) LIKE "%giloralimab%" OR LOWER(drugSynonyms_string) LIKE "%giloralimab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2944', 'drugName': 'Giloralimab', 'tradeNames_string': '', 'drugSynonyms_string': 'ABBV-927, Abbv-927, Giloralimab, PR-1614645', 'linkedDiseasesDrug_string': 'Pancreatic Carcinoma (EFO_0002618), Cancer (MONDO_0004992), Head And Neck Malignant Neoplasia (EFO_0006859), Breast Cancer (MONDO_0007254)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'CD40 (ENSG00000101017)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.121 | Q17 | What gene does the drug Vilanterol .Alpha.-Phenyl Cinnamate target? | The drug Vilanterol .Alpha.-Phenyl Cinnamate is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene ADRB2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%vilanterol .alpha.-phenyl cinnamate%" OR LOWER(tradeNames_string) LIKE "%vilanterol .alpha.-phenyl cinnamate%" OR LOWER(drugSynonyms_string) LIKE "%vilanterol .alpha.-phenyl cinnamate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3869', 'drugName': 'Vilanterol .Alpha.-Phenyl Cinnamate', 'tradeNames_string': '', 'drugSynonyms_string': 'GW-642444H, GW642444H, Gw642444h, Vilanterol .alpha.-phenyl cinnamate', 'linkedDiseasesDrug_string': 'Chronic Obstructive Pulmonary Disease (EFO_0000341)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1322 | Q17 | What gene does the drug Naproxen Sodium target? | The drug Naproxen Sodium targets 2 genes: PTGS2 and PTGS1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%naproxen sodium%" OR LOWER(tradeNames_string) LIKE "%naproxen sodium%" OR LOWER(drugSynonyms_string) LIKE "%naproxen sodium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5291', 'drugName': 'Naproxen Sodium', 'tradeNames_string': 'Aleve, Anaprox, Anaprox ds, Naprelan, Naproxen sodium, Synflex', 'drugSynonyms_string': 'BAY-117031, BAY117031, BAYH6689, Naproxen sodium, Naproxen sodium anhydrous, Naproxen sodium salt, RS-3650', 'linkedDiseasesDrug_string': 'Gout (EFO_0004274), Toothache (EFO_0010072), Alzheimer Disease (MONDO_0004975), Pharyngitis (MONDO_0002258), Tendinopathy (EFO_1001434), Osteoarthritis (MONDO_0005178), Ankylosing Spondylitis (EFO_0003898), Juvenile Idiopathic Arthritis (EFO_0002609), Migraine Disorder (MONDO_0005277), Pain (EFO_0003843), Osteoarthritis, Knee (EFO_0004616), Back Pain (HP_0003418), Frozen Shoulder (EFO_1000941), Gastric Ulcer (EFO_0009454), Dysmenorrhea (HP_0100607), Rheumatoid Arthritis (EFO_0000685)', 'yearOfFirstApproval': 1980, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1221 | Q17 | What gene does the drug Benserazide target? | The drug Benserazide targets the gene DDC. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%benserazide%" OR LOWER(tradeNames_string) LIKE "%benserazide%" OR LOWER(drugSynonyms_string) LIKE "%benserazide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2020', 'drugName': 'Benserazide', 'tradeNames_string': '', 'drugSynonyms_string': 'Benserazide, Benserazide (as hydrochloride), Benserazide hcl, Benserazide hydrochloride, NSC-755907, RO 4-4602, RO-4-4602, Serazide', 'linkedDiseasesDrug_string': 'Parkinson Disease (MONDO_0005180), Restless Legs Syndrome (EFO_0004270)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DDC (ENSG00000132437)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.528 | Q17 | What gene does the drug Etonogestrel target? | The drug Etonogestrel targets the gene PGR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%etonogestrel%" OR LOWER(tradeNames_string) LIKE "%etonogestrel%" OR LOWER(drugSynonyms_string) LIKE "%etonogestrel%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6181', 'drugName': 'Etonogestrel', 'tradeNames_string': 'Implanon, Nexplanon', 'drugSynonyms_string': 'Etonogestrel, Implanon, ORG 3236, ORG-3236', 'linkedDiseasesDrug_string': 'Hiv Infection (EFO_0000764), Benign Prostatic Hyperplasia (EFO_0000284), Dysmenorrhea (HP_0100607), Aids (EFO_0000765), Pregnancy (EFO_0002950)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PGR (ENSG00000082175)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.